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Abstract
Neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer’s Disease (AD)
and Huntington’s Disease (HD) have no cure despite intensive research efforts geared towards
therapeutics development. In the USA, patients with PD and AD alone cost the nation ~ $200
billion annually in patient care and lost productivity. Therefore, there remains an urgent and unmet
need to develop novel drugs and drug carriers with the potential to slow down, halt and ideally
reverse the course of neurodegenerative disorders.
The dissertation focuses on developing approaches towards targeting PD using
multifactorial mechanisms including the targeting of protein aggregation and oxidative stress. This
is important because previous reports have revealed that protein aggregation and oxidative stress
interact and intensify each other's effect in PD, ultimately resulting in neuronal death. A section of
the dissertation underscores overcoming solubility and bioavailability limitations associated with
ellagic acid (EA), a polyphenol with excellent antioxidant potential, using chitosan (CS)
nanoparticles as nanocarriers. Our results reveal that encapsulation of EA in CS-based nanoensembles results in mitigation of the PD-associated toxic effects and furthermore, overcomes
solubility-related issues of the parent drug. In continuing with this theme, effort is drawn towards
developing carbon quantum dots as inhibitors of amyloid fibrillation and as antioxidants. We
showcase the development of a "one-pot" drug which also intervenes across multiple disease
outputs. This facet is becoming increasingly important as diseases are being recognized as not
being monogenic in nature but instead as progressing via a plethora of molecular aberrations that
are sporadic/idiopathic. Finally, we advance analytical tools that promote a facile and costeffective method to address the soluble-to-toxic transformation of amyloidogenic proteins. The
methodological inroad is rapid, inexpensive, and quantitative and diminishes existing barriers
associated with techniques to evaluate fibril formation and intervention.
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Chapter 1: Introduction
1. OVERVIEW OF NEURODEGENERATIVE DISEASES
Neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) 1
are debilitating neurological disorders with no available disease-modifying therapies present for the
patient despite intensive and on-going research in this area for more than two centuries2. AD is a
cognitive neuro-affliction impacting more than a million people and accounts for more than 50%
dementia cases in the United States alone. The standard presentation of the disease includes decline in
thinking, behavioral and social skills, making an individual incapable of functioning independently and
ultimately results in death of an individual. Whereas PD is an illustrative example of movement
neurodegenerative disorders clinically characterized by tremors on one or both sides of the body,
bradykinesia, rigidity, and postural instability affecting more than half a million people in the United
States alone

2-4

. The word neurodegeneration derives its origin from the Greek prefix néuro meaning

“nerval” and the Latin verb de̅genera̅re meaning “decline”. The term “neurodegenerative diseases” is
a broad class of diseases which includes a range of conditions, all arising from the progressive
degeneration and destruction of the neurons leading to dysfunction, disabilities and ultimately death of
an individual 2-4. As the amount of dead neuronal cells increases, it eventually results in deterioration
of the affected brain regions of the nervous system which then begins to shrink: hippocampal region in
AD and substantia nigra in PD 2-4. This destruction of the nerve cells can either result in impairment of
movement as in the case of PD or dementia (impairment of memory or cognitive abilities) as in the case
of AD2-4. According to a report, the neurodegenerative diseases will be the second leading cause of
death around the world after the cardiovascular diseases in the next twenty years2-4. This points towards
the urgent and unmet need for the development of novel drugs and drug carriers with the potential to
slow down or halt the course of these neurological disorders 2-4.
1.1. Molecular Outcomes
These neurological diseases share common mechanisms and phenotypes and at molecular level
various factors can induce neuronal death. Some of these factors are aberrant protein aggregation,
oxidative damage, impaired autophagic flux, impaired bioenergetics, and mitochondrial dysfunction to
name a few 2-4. This section highlights two main molecular outcomes associated with neurodegenerative
disorders namely protein misfolding & aggregation and oxidative stress which are the focus of this
research work.
1

1.1.1. Aberrant protein misfolding
The misfolding of amyloidogenic proteins into fibrillar aggregates and their extracellular
deposition as plaques or as intracellular inclusions is the molecular hallmark of amyloid-related
disorders such as AD and PD. These plaques act as the accumulation site for various proteinaceous and
non-proteinaceous elements (e.g., metal ions) present inside the organ. The intracellular inclusions
interfere with the cellular physiology by either disrupting the calcium homeostasis or by interfering
with the intracellular protein or RNA transport or sequestering the chaperone proteins. These amyloid
depositions of functional protein precursors into aggregates are collectively termed as amyloidosis.
These misfolded proteins are associated with various neuropathological conditions such as AD and PD
(Fig 1) 1-4.

Substantia nigra

Hippocampal region
plaque

inclusions

Figure 1: Schematic representation of neuronal cells displaying molecular hallmarks of PD
(inclusions) & AD (plaques). Reproduced with permission from Ref 5.
The amyloid fibrillates through three kinetic phases, namely nucleation, elongation, and
saturation in the primary nucleation (Fig. 2). This trend can be visualized over time using the fluorescent
dyes such as Thioflavin T (ThT). Comparatively, the lag phase is considered as the rate-limiting step as
it requires overcoming one or more free energy barriers. The outcomes of these kinetic transitions are
unusual oligomers, protofibrils, and amyloid fibrils, which are pathogenic 1-4.

2

Oligomers

Secondary
neucleation
Secondary nucleation
Depolymerization

Unfolded protein

Intermediate

Fibril yield

Oligomers

Protofibrils
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inclusion

Fragmentation
Native protein
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Nucleation phase

Stationary phase

Figure 2: The different stages of amyloid misfolding. Reproduced with permission from Ref 5.
Fibrillar assemblies are an outcome of protein misfolding-refolding, which results in the
formation of insoluble amyloid fibrils via the nucleation-extension growth process (Figure 2) 6. The
obvious outcomes of this protein misfolding process are protein aggregation, loss of biological
function and gain of toxicity (Fig. 3).
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(folded structure)
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Figure 3: Schematic representation of amyloid misfolding and associated outcomes.
Misfolding can originate from point mutation(s) or interaction with external or internal toxins,
oxidative damage, impaired post-translational modifications of the protein or impaired trafficking 4. All
3

these factors can affect protein folding independently or in association with each other. The fibrils from
different pathologies such as AD and PD share some common properties such as a core cross beta-sheet
rich secondary structure in which continuous beta-sheet are present, with each beta-strand running
perpendicular to the long axis of the fibrils. This beta-sheet rich structure of fibril is responsible for its
resistance to amyloid degradation and insolubility resulting in deposition of the misfolded protein
(plaques and inclusions) 4, 6.
Studies have shown that oligomers and protofilaments are more toxic than fibrils. For example,
in case of alpha-synuclein which is responsible for the onset of PD, three different mechanisms of
neurotoxicity have been proposed

1-4

. An increase in the monomeric form due to duplication or

triplication of the alpha-synuclein gene is an example of familial form of PD and is associated with
intracellular elevation of monomeric species. This intracellular abundance is associated with
neurotoxicity

1-4

. Whereas other studies have shown that oligomers can form pores in intracellular

membranes, increasing the cations permeability inside the neurons. Furthermore, studies have also
shown that fibrils can cause neuronal dysfunction and death by affecting proteasome functions,
disrupting ER and Golgi apparatus, impairing axonal transport, and disrupting the cell membrane (Fig.
4) 1-4. However, a complete understanding of the exact nature of amyloid toxicity is still to be realized
4, 6, 7
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Figure 4: Schematic representation of amyloid aggregation and associated outcomes.
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1.1.2. Oxidative Stress
The oxidative stress is a causative agent of various pathophysiological conditions such as cancer,
heart disease, allergies, and neurodegenerative diseases. The cellular response is altered under such
oxidative stress conditions resulting in a diseased state. Some of the reasons responsible for the brain
to experience higher oxidative damage is the high consumption of oxygen (20 % of the total),
accumulation of metals with age, high levels of iron and ascorbate, comparatively low levels of natural
antioxidants (catalase) and low regenerative capabilities 4. Furthermore, microglia and astrocytes in the
brain produces cytokines which have been studied to generate Reactive Oxygen Species (ROS) and
Reactive Nitrogen Species (RNS) (e.g. NO) thus acting as the mediators of inflammatory processes
along with the P450s in certain brain regions. Furthermore, the human body produces free radicals,
such as ROS and RNS, as part of the normal biochemical reactions 4, 6-8. To maintain the level of free
radicals under control and to avoid their harmful effects, our bodies have evolved self-defense
mechanisms in the form of various enzymes such as glutathione, catalase, and superoxide dismutase
(SOD) which can effectively 'neutralize' these free radicals by enhancing cellular defense mechanisms
4, 6-8

. However, the problem arises when this balance is perturbed, whether it be because of a genetic

mutation in one of these enzymes (as is the case in some patients with Amyotrophic Lateral Sclerosis
with a mutation in SOD gene) or because of the increased environmental exposures to the toxic
compounds (Fig. 5). Such elevated production and exposure results in the attack of all major
biomolecules (proteins, DNA/RNA, carbohydrates, and lipids) by these free radicals. The
polyunsaturated fatty acids (PUFA) composing the cell membranes are one of the main target sites of
these free radicals which then causes lipid peroxidation 4, 6-8. The active byproduct of lipid peroxidation
is an aldehyde that can quickly diffuse from the site of the attack to the other parts of the cell and tissue
resulting in tissue damage and onset of chronic diseases. On the other hand, the hydroxyl radicals have
been observed to react with the DNA resulting in the oxidative damage of the sugar moiety of the
oligonucleotides and the heterocyclic base moiety resulting in DNA strand breaks and generation of
base-free sites in the DNA 4,7. The outcome of such reactions is the generation of impaired doublestranded DNA (dsDNA), which can induce mutagenesis, carcinogenesis, senescence, etc. Furthermore,
free radicals in the form of activated oxygen species, in the presence of Fe2+ and Cu2+, can induce
oxidative damage to the proteins arising due to the modification of the amino acids, forming peroxides
and carbonyls 4,7. Amino acids, such as proline, lysine, arginine, and histidine, are the most sensitive to
such oxidative damage. Such oxidative damage results in generation of oxidized proteins, which is
highly correlated to various pathophysiological conditions such as neurodegenerative diseases
5

4,7

.

Another target of the free radicals is the powerhouse of the cell, viz., the "mitochondrion." The oxidative
damage to mitochondria results in mitochondrial dysfunction which, in turn, can result in (i) reduced
amount of energy to the affected cell, (ii) disruption of calcium homeostasis (an essential secondary
messenger inside the cell), (iii) collapse of mitochondrial proton motive force, (iv) reduced
mitochondrial membrane potential, and (v) can also activate a cascade of signaling pathways resulting
in cell apoptosis (programmed cell death)

4,7

. Therefore, it is not surprising that although AD & PD

differ in etiology, symptoms and brain region affected, the oxidative stress is considered as an important
pathway which leads to neuronal death in both the diseases.
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Figure 5: Schematic representation of the various factors responsible for the onset of the oxidative
stress.
2. MAIN CHALLENGES AND RESEARCH QUESTION
Since the formation of fibrillar aggregates from polymerization of the soluble native protein
and the associated onset of oxidative stress (and vice-versa) is an intractable problem, the successful
early diagnosis and treatment for AD & PD are still limited, unlike any other disease

1, 9-12

. These

disorders serve as a potential burden not only on the patient but also on the family, caretakers, and the
economic front of the health system of a country. Interestingly, the risk of the population affected by
neurodegenerative diseases correlates directly with the advancing age 1, 9-12. With increased lifespan in
western countries, the financial and mental burden arising from neurodegenerative diseases is predicted
to grow and become more profound in both society and economy of a nation 1, 8-11.
Furthermore, the majority of currently available treatments are symptomatic and are not reliable
enough to stop, halt, or ameliorate the diseased condition. Based on the global statistics, in the
6

upcoming years, more and more people are prone to AD & PD, which drives the need of furthering our
knowledge of this disease process and better understanding of the involved amyloidogenic proteins and
their mode of aggregation, the onset of oxidative stress (or vice-versa) and hence disease onset 1, 8-11. It
also points towards the importance of development of new approaches for early detection, and
treatment, if not a cure, for the gravest of human diseases arising from amyloid misfolding and
associated aggregation and findings ways to prevent the disease from happening in the first place itself,
if possible 1, 8-11.
3.

DISSERTATION CONTRIBUTION

This dissertation involves (i) development of nanocarriers for controlled and sustained release
of an encapsulated drug, (ii) synthesis and characterization of multifunctional Carbon-based
nanomaterials (CNMs) as inhibitors of amyloid fibrillation and free radical scavengers, and (iii)
development of cost-effective and facile method to resolve soluble-to-toxic transformation of amyloid
proteins.

3.1. Polymeric nanoparticles (pNPs) as drug delivery systems
These have a size between 10 to 1000 nm and are made up of polymers and copolymers
protecting a drug, either encapsulated within the nanoparticle or adsorbed or chemically linked to the
surface of the nanoparticle 13-16. The pNPs used in this study are prepared using Chitosan because of its
excellent properties such as biodegradability. Chitosan can be readily removed from the system by the
action of hydrolases and lysozyme in mammals and the end products are non-harmful alcohols and
other low molecular weight products that can be excreted out of the body 16. Furthermore, these pNPs
increase the solubility of active drugs, provide reasonable pharmacokinetic control, are non-toxic, noninflammatory, and can escape reticuloendothelial clearance 15. As a result, these pNPs can be used for
drug-delivery applications. In this work, Chitosan was used as a nanocarrier to deliver Ellagic acid.
Despite its great therapeutic potential that the polyphenol (Ellagic acid) holds, its application is limited.
This can be attributed to the low solubility, low permeability, and poor transport across the biological
membranes17. Therefore, the first part of this research work involves encapsulation of a potent
antioxidant inside a polymeric nanoencasement which is not a passive container but displays inherent
neuroprotective capability. This encapsulation allowed enhanced drug availability at the target site,
controlled and sustained release of the drug and synergistic antioxidant capabilities of our nanohybrid
was also observed 18-25.
7

3.2. Carbon Quantum Dots (CQDs) as free radical scavengers and inhibitors of amyloid
fibrillation
These NMs are zero-dimensional nanosized carbon particles (size between 2-10 nm) with inherent
strong fluorescence characteristics 23. These are mono-dispersed spherical nanoparticles with a carbonbased skeleton and a large amount of oxygen-containing (-OH and -COOH) and amine bearing (-NH2)
surface functionalities. The structure of CDs is composed of sp2 hybridized carbon interior and an
amorphous shell containing functional groups on the edges

26

. Some of the exciting chemical and

physical properties of these nanomaterials include high aqueous dispersibility, excellent
biocompatibility, chemical inertness, large surface-to-volume ratio, low toxicity, tunable
photoluminescence, unique optical properties, chemical stability, ease of surface modification,
resistance to photobleaching and feasible and facile synthesis methods. Since their accidental discovery
in 2004 during electrophoretic purification of SWCNTs, these newcomers to nanomaterials have
attracted attention of scientific community worldwide as an environmentally friendly replacement of
toxic quantum dots (QDs). These NMs display broad range of application in the biomedical field such
as bioimaging agent, chemical sensing, disease-detection and as nanomedicine 27-31.
In the second section of our work, four different CQDs were synthesized, and their neuroprotective
potential was assessed. In the first part, three different CQDs that were synthesized from three different
organic acids were investigated for their potential as a multifunctional material (antioxidant, inhibitors
of amyloid fibrillation, and bioimaging agent). In the second part, CQDs prepared from gelatin were
evaluated for their ability as a neuroprotectant against paraquat-induced neuronal demise in vivo and
in vitro.
3.3. An assay to resolve and quantify soluble-to-toxic transformation of amyloid proteins
The third approach of our research work is developing a rapid, facile, cost-effective assay to
quantify the soluble-to-toxic transformation of amyloid protein. Efforts to develop an understanding of
this biophysical transformation are driven by spectroscopic and immunohistochemical tools.
Nevertheless, access to instruments such as solid-state NMR, microscopes (TEM, HR-TEM, SEM,
AFM), ATR-IR, DLS instruments and biochemical kits preclude routine studies of the process for many
laboratories and investigators. Even if high-resolution microscopes are accessible, extensive sample
preparation protocols, analyses times, and availability of very specific technical/instrumentation
expertise are barriers that still needs to be overcome. Finally, and critically, higher-resolution structural
8

techniques are not amenable to quantification and kinetics measurements. In conclusion, we
demonstrate that a readily existing method and easily accessible apparatus can be used to obtain rich
biophysical (kinetic) data about amyloid forming trajectories and the interplay between intermediates
therein. Equally importantly, it can be used to screen small-molecules and determine, via size analysis,
where along the trajectory that the small- molecule intervenes32-37.

9

Chapter 2: Chitosan-Ellagic acid nanohybrid for mitigating rotenone-induced oxidative stress
ABSTRACT
Antioxidants derived from nature, such as Ellagic acid (EA), demonstrated high potential to
mitigate neuronal oxidative stress and related pathologies, including Parkinson's disease (PD).
However, the application of EA is limited due to its toxicity at moderate doses and poor solubility,
cellular permeability, and bioavailability. Here, we introduce a sustainably-resourced, green
nanoencasement strategy to overcome the limitations of EA and derive synergistic effects to prevent
oxidative stress in neuronal cells. Chitosan, with its high biocompatibility, potential antioxidant
properties, and flexible surface chemistry, was chosen as the primary component of the nanoencasement
in which EA is immobilized. Using a rotenone model to mimic intracellular oxidative stress, we
examined the effectiveness of EA and chitosan to limit cell-death. Our studies indicate a synergistic
effect between EA and chitosan in mitigating rotenone-induce reactive oxygen species death. Our
analysis suggests that chitosan encapsulation of EA reduces the inherent cytotoxicity of the polyphenol
(a known anti-cancer molecule). Furthermore, its encapsulation permits its delivery via a rapid burst
phase and a relatively slow phase making the nanohybrid suitable for drug-release over extended time
periods.
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1. INTRODUCTION
Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder
and disturbs organismal locomotor function. The onset of PD is characterized by the degeneration of
predominately dopamine-producing ("dopaminergic") neurons in the substantia nigra and the
formation of Lewy bodies comprised of α-synuclein (and synphilin-1) aggregates

38-41

. While the

etiology of PD is not clearly established, a general consensus exists that a combination of factors
including aging, specific mutations, and environmental toxins such as pesticides can trigger the
pathology. A large subsection of non-familial sporadic PD is an outcome of intracellular oxidative stress
42-44

. Disruption in mitochondrial homeostasis or the process of controlling intracellular metabolism is

the primary mechanism through which reactive oxygen species (ROS) are generated in the cell45, 46.
The stress induced by the cellular ROS production is one of the proposed mechanisms for dopaminergic
neuronal death in sporadic PD 45, 46.
Neuronal cells are particularly susceptible to oxidative stress generated through impairment of
mitochondrial activity 47. Rotenone is a broad-spectrum insecticide and piscicide that is an established
disrupter of mitochondrial homeostasis in neurons through its binding to complex I of the mitochondrial
respiratory chain 47-50. Owing to its small and hydrophobic structure, rotenone easily crosses the blood
brain barrier (BBB) and causes neuronal cell death 51, 52. Increasing epidemiological evidence suggests
an association between Parkinson's disease and past exposure to rotenone 47-50. A recent study indicated
that rotenone reproduces key PD features such as motor deficits and loss of dopaminergic neurons 38,
52

indicating the urgent need to develop mitigation strategies for rotenone-induced oxidative stress and

associated neuropathies and making rotenone a model compound for generating the PD phenotype in
cells and preclinical studies53, 54.
Two primary approaches have been proposed to attenuate the effects of oxidative stress on
striatal dopaminergic neurons; viz., treatment with i) small molecules and ii) nanoformulations

54-71

.

Among various small-molecule drugs, the free-radical scavenging capabilities of small- molecules
derived from nature including gallic acid, ellagic acid (EA), vitamin E, epigallocatechin gallate, and
curcumin and its consequent therapeutic properties are well-documented. However, poor aqueous
solubility, low permeability, cytotoxicity with increasing dosage, and "first-pass effect" has limited the
small molecule from gaining therapeutic value

54-62

. To enhance the bioavailability and mitigate

solubility issues, encapsulation of the drug (e.g., small molecules) in a nanocarrier was proposed 69-71.
Some examples of nanotherapeutics include lactoferrin conjugated glial cell-derived neurotrophic
factor (GDNF) encapsulated nanoparticles (NPs), RNAi immobilized dendrigraft poly-L-lysines NPs,
11

Polyamidoamine (PAMAM), phosphorous dendrimers (pd), viologen-phosphorous dendrimers (vpd),
and ropinirole-loaded poly (lactic-co-glycolic acid) PLGA NPs 68-72. Nevertheless, most of the proposed
strategies suffer from inferior biodegradability, biocompatibility, and in most cases the highly synthetic
nature of the constituents (of the examined nanocarriers). Hence, recent research is focused on
developing highly biocompatible nanoencapsulated antioxidants from sustainable materials to prevent
neurodegenerative diseases.
In addition, current nano-based antioxidant delivery systems are limited by nano-enclosures
carrying the small molecules which only serve as passive containers and do not complement the
activities of the drug. Intelligent design of nanocarriers using materials with known antioxidant
capabilities can potentially lead to synergistic effects and enhanced prophylactic therapeutic efficacy.
Hence, this work aims to formulate a unique, highly sustainable hybrid nanosystem where both the
carrier and the core are antioxidants and therefore can mitigate oxidative stress in neurons. Considering
the known antioxidant properties and highly sustainable nature, chitosan and ellagic acid (2,3,7,8tetrahydroxybenzopyrano [5,4,3-cde] benzopyran-5-10-dione) were selected as the primary component
for the enclosure and drug, respectively54,

57, 73-76

. Chitosan (CS) is a biodegradable linear

polysaccharide derived from chitin shells of shrimp and other crustaceans with previously documented
biocompatibility, antioxidant property, and permeability-enhancing properties 18-25, 73-75, 77-87. Ellagic
acid, a polyphenol found in fruits and vegetables and possesses a wide-spectrum of biological activities
such as antioxidant, anti-viral, anti-cancer, and anti-mutagenic properties, with potential toxicity at
higher doses 54, 76, 88-92.
Encapsulating EA can control its release and can potentially alleviate its poor aqueous solubility,
and low cellular permeability 54. Hence, building on our CS nanoparticle-based antioxidant design, we
demonstrate a green route to synthesize a hybrid antioxidant formulation comprising CS and EA to
surmount oxidative stress in neurons. We couple the vehicle to polyethyleneglycol (PEG) to further
enhance its water solubility. The neuroprotective effect of proposed nanohybrid on SH-SY5Y cell line
is studied. Based on the data gathered via cytotoxicity, apoptosis, ROS quenching, and mitochondrial
membrane potential assays, we conclude that our nanoensemble could be developed as a novel
prophylactic system for the mitigation of oxidative stress-induced by rotenone exposure. To the best of
our knowledge, this is the first study illustrating a nanohybrid comprising of EA and PEG-CS with
prophylactic efficacy against rotenone insult in neuroblastoma cells. The highly sustainable, and
inexpensive nature of the formulation makes it a potentially superior, environmentally friendly
alternative to synthetic compounds to rescue cells from rotenone insult.
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2. RESULTS AND DISCUSSION
2.1. Synthesis and spectroscopic characterization of EA loaded CS particles
The synthesis of EA loaded CS particles involved the electrostatic anchoring of EA onto CS,
crosslinking of CS using TPP, and immobilization of PEG to improve the surface properties (Figure 6
A). We followed the reaction using FTIR and XRD (Figure 6 B & C) to confirm the completion of each
step including the formation of ellagic acid encapsulated PEG coated chitosan nanoparticles
(EA@PCS).
Initially, we tested the feasibility of preparing PCS nanoparticles without EA loading. For this, the
amino group at C-2 position in chitosan was protonated using aqueous acetic acid. Subsequently,
chitosan was cross-linked using TPP through the electrostatic interaction between the amine groups on
chitosan and the negatively charged polyanion TPP (Figure 6 A). Initial chitosan powder samples had
prominent features at 1648, 1550, and 1453cm-1 corresponding to amide I, II and III vibrations,
respectively. The crosslinking and the formation of CS NPs resulted in the emergence of a new feature
at 1155 cm-1 due to the P=O vibration of TPP, confirming the crosslinking (Figure 6 B). Anchoring of
PEG through dipole-dipole interactions or H- bonding between the C-6 hydroxyl group of CS and
hydroxyl and etheric oxygen group of PEG was confirmed through the presence of absorption features
at 2878 cm-1,1457 cm-1, and 856 cm-1due to the C-H stretching and CH2 bending in PEG and CH2OH
group in CS 20, 22, 24, 79, 80.
After spectroscopically confirming the successful fabrication of the vehicle, we prepared
EA@PCS through a slightly modified protocol. Since our design involved EA both on the outside and
inside of the vehicle (for burst release and sustained release as explained later), the EA was first
anchored on the chitosan surface. Being a polyphenol, EA possess 4 interacting hydroxyl groups ( two
at meta position and two at para position, evidenced by the broader feature around 3000 to 3300 cm-1
in the IR spectrum in Figure 6 B) that can interact with amine functionalities present in CS

84

. The

formation of EA-chitosan composite before the preparation of NPs, ensured that EA was both on the
inside and outside of the PCS NPs. The amine groups in CS resulted in a broader feature in 3000-3500
cm-1 range. The change in the profile of vibrational features beyond 3000 cm-1 in EA@PCS NPs
compared to CS and PCS and its close similarity to EA reflects the immobilization of EA in EA@PCS
system. The presence of characteristic absorption bands at 1648 (amide I), 1550 (amide II), and 1453
(amide III) from CS, 2878 cm-1 and1457 cm-1due to the C-H stretching and bending vibration of PEG
in EA @PCS spectrum further confirmed the formation of EA@PCS 82, 83, 93, 94. The absorption peaks
for EA at 1710 cm-1 (C=C aromatic stretching) and 1606 cm-1 (C-C stretching) that was evident in the
13

EA spectrum is probably masked by the amide vibrations in EA@PCS spectrum 82-84. The spectrum of
EA@PCS NPs also exhibited peaks at 1155 cm-1 corresponding to the linkage between phosphate
groups of TPP and amino group of CS

84

. Thus, the IR spectrum clearly indicated the successful

formation of EA@PCS NPS as proposed (Figure 6A).
The phase purity and crystallinity of the samples, as well as the presence of various synthetic
ingredients in the EA@PCS NPs was further established using XRD (Figure 6 C). Between chitosan
and EA, pure EA displayed a typical crystalline XRD pattern with the most prominent peak at 2q value
27.9o and chitosan demonstrated a largely amorphous nature (diffraction peak not shown)

24, 25, 78-80

.

The crosslinker used in the study, TPP which is crystalline with 2 phases (i.e. phase I and Phase II),
depicted characteristic diffraction peaks at 2q = 21.8o, 22.4o, 22.8o, 26.7o, 27.8o, 31o, & 32.9o as apparent
in the CS and PCS nanoparticles diffraction pattern (Fig 6C). The prepared CS NPs demonstrated
higher crystallinity compared to parent chitosan mostly due to the presence of TPP crosslinker. The
addition of PEG, and its anchoring, did not result in any observable changes in the crystallinity of the
PCS nanoparticles (Fig 6C). Furthermore, the PCS nanoparticles also demonstrated the diffractions
from TPP. However, the addition of EA into the nanoensemble resulted in a general decrease in the
overall crystallinity. The incorporation of EA can exert steric interactions on the intra- and intermolecular H-bonding within PCS nanoparticles and electrostatic interactions between PCS and TPP
leading to a general decrease in the crystallinity in EA@PCS NPs 84. However, peaks at 2q values of
18.2o, 22.4o, 26.7o, & 31o corresponding to TPP and 27.9o and 23.6o corresponding to EA in EA@PCS
reconfirmed the immobilization of EA. The DSC measurements also suggested a decrease in
crystallinity of the sample after the incorporation of EA into PCS (Figure S2).
A decrease in the glass transition temperature from ~110oC for CS to ~90oC in EA@PCS was
observed in the DSC. This decrease in the glass transition temperature suggests that interaction between
EA and PCS can result in reduced stiffness and crystallinity of the NPs 84. Our UV/VIS spectral and
HPLC chromatogram studies of the as-synthesized EA@PCS NPs also indicated the incorporation and
presence of EA in EA@PCS (Figure S1). The absorption spectrum of EA displayed a prominent feature
at 254 nm (corresponding to a p to p* transition) and a shoulder at 360 nm pointing to the n to p*
transition in EA. Hence, the presence of absorption peaks at 254 nm and 360 nm in EA@PCS sample
indicate the immobilization of EA in the PCS NPs. Immobilization and the delayed release of EA from
the delivery vehicle was confirmed using HPLC as well. The delay in elution of EA from EA@PCS is
plausibly due to the non-bonding interaction between the amine groups in the PCS and hydroxyl groups
on the EA as indicated in the scheme (Figure 6 A).
14
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Figure 6: Schematic representation of proposed mechanism (A). FTIR spectra (B) and XRD
diffractograms of TPP, CS powder, CS, PCS, EA and EA@PCS(C). Reproduced with permission
from Ref 95.
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2.2. Investigating the surface charge and Morphology of EA@PCS NPs
Figure 7 depicts characteristics of the as-synthesized EA@PCS NPs using DLS and a host of
microscopic techniques. The surface charge and size of NPs can provide information about their
stability in solutions. The presence of polarizable functional groups on the surface of EA@PCS is
expected to impart and control their surface charge. Figure 7 A shows the zeta potential (DLS studies)
of CS, PEG, TPP, PCS and EA@PCS NPs. A positive zeta potential of 24.17 mV was recorded for CS
NPs which is attributed to the protonated amine groups present on the surface. The high positive value
of zeta potential can lead to enhanced stability and can prevent them from aggregating. The formation
of EA@PCS resulted in a reduction in zeta potential to 16.5± 2.6 mV presumably due to the partial
neutralization of amino groups through hydrogen bonding with hydroxyl group of EA on the surface.
However, both PCS and EA@PCS formed dispersion due to the presence of functional groups from CS
and PEG. Figure 7 B shows the average hydrodynamic diameter of CS, PCS, and EA@PCS NPs using
DLS. An average size of 149.5 nm was recorded for CS NPs whereas 275 nm was observed for
EA@PCS NPs. This increase in size could be attributed to the incorporation of drug in the
nanoparticles.
Electron microscopy was employed to directly observe the morphology of the prepared NPs.
SEM image from lyophilized samples (Figure 7 C) indicated that EA@PCS NPs are mostly elliptical
with rough surface. Particles of different sizes were observed in the SEM possibly due to the
aggregation induced by the lyophilization. During lyophilization, the concentration of NPs will
gradually and continuously increase due to the progressive removal of solvents. The increase in NP
concentration can force the particles to aggregate and form bigger particles through extensive hydrogen
bonding to minimize the total surface energy of NPs (Figure 7 B). The EDX analysis indicated the
presence of only C, N, O, and P in EA@PCS nanoparticles (inset Figure 7 C) confirming that the
prepared nanoparticles were generally devoid of any contamination. Trace amounts of Na+ was also
observed which can be attributed to the use of sodium salt of TPP. The presence of smaller individual
particles was confirmed through TEM analysis of EA@PCS sample. Figure 7 D depicts the TEM image
of individual EA@PCS showing an average size of 200 nm, slightly lower than the one predicted by
DLS. The increased size obtained via DLS analysis can be reconciled by considering that the
measurement was carried out in the suspended form in a water-acetic acid mixture which is known to
swell CS NPs 84. Hence, compared to the dried samples used for TEM (and SEM) investigations, the
hydrodynamic diameter of EA@PCS will be higher. Dried EA@PCS NPs were also examined using
AFM (Figure S3) to characterize the three-dimensional morphology of the NPs. The AFM results
16

further confirmed the average lateral dimension of the NPs to be ~200 nm and the height was observed
to be 50 nm again indicating the elliptical nature of the prepared particles.
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Figure 7: DLS analysis of the obtained EA@PCS NPs (A-B), and SEM and TEM images of
EA@PCS NPs (C-D). Reproduced with permission from Ref 95.

2.3. Determination of Entrapment Efficiency (%) of the nanoparticles and Drug release
studies
After examining the surface chemistry and morphology of the nanoensemble, we calculated the
drug entrapment efficiency and loading capacity of the EA@PCS. For a drug concentration of 6 mg,
an entrapment efficiency (%) of 65.79 ± 3.593% was obtained. From the residual EA present in the
supernatant and the drug entrapment efficacy, we calculated the exact amount of EA and PCS present
in the EA@PCS sample (Figure S4). Hence when we compare the activities of 60 µg of controls and
EA@PCS, we are comparing the activities of 60 µg of EA and 60 µg of CS with 60 µg of EA@PCS
(that has 0.68 µg of EA and 59.32 µg of PCS). The higher antioxidant activity demonstrated by
EA@PCS even at lower individual amounts of the components indicates the synergistic activity of the
17

nanohybrid. Our results were in accord with the previous findings on a similar system 84. The EA@PCS
NPs with confirmed loading of the drug was subsequently investigated for their drug release profile.
For the ideal performance of a drug, the drug-carrier ensemble should be able to release the drug
in a gradient fashion. For example, while the slow release over longer period (sustained release) is
necessary to increase the bioavailability of the drug, if there is an urgent need (as in the case of acute
ROS attack), the drug should be released immediately in high concentrations (burst release). To
ascertain the feasibility of burst and sustained release of EA from the PCS enclosure, we conducted the
drug release profile of EA from EA@PCS NPs (Figure 8A). Within the first 5 hours of EA@PCS
exposure to physiological pH (pH= 7.4), a release of ~ 50-60% of EA was seen. The initial burst release
could be due to the release of EA that are otherwise immobilized on the surface of EA@PCS NPs
through the electrostatic interaction between hydroxyl groups of EA and amino group of CS backbone.
The initial release was followed by a slow and sustained release kinetics (presumably from the interior
of the NPs) depicting the controlled release capabilities of our EA@PCS system. The slower release is
presumably due to the release of EA trapped inside the PCS vehicle through the pores on PCS. The
drug loading was done at pH=5 where the particles are swelled which allows the drugs to enter the PCS.
Upon increasing the pH, the particle shrinks resulting in the drug entrapment. The porosity data revealed
that even at pH 7.8, there is ~14% porosity in EA@PCS. Hence, we hypothesize that at pH of 7.5, a
sustained release can occur from the ensemble. The burst release phase (initial hour of exposure) should
typically contain the release of EA that is adsorbed on the outer surface of PCS as well as EA coming
from the interior. After exhausting the externally anchored EA, a slow sustained release occurs from
the interior through pores 96-99 (Figure S 4). To confirm the burst and sustained release of the drug from
the EA@PCS, we conducted another drug release profile study before and after the wash (supporting
information Fig S 4). After the wash, we observed a sustained release of the drug. This could be
attributed to the fact that during the wash the surface adsorbed EA were released into the release media
and thus we did not observe any burst effect. The presence of a high initial slope and the knowledge
that before the sustained drug release, generally a burst release of the drug happens, indicates the
biphasic drug release of EA@PCS

100-103

.This leads to the ability of the system to deliver EA either

through burst release or a slow sustained release mechanism.
2.4. EA@PCS as an antioxidant to prevent neurodegenerative disorders
Akin to rotenone-induced PD, ROS-induced damage is known to be substantial in the case of
other pathologies as well. Hence, we explored the utility of as-synthesized EA@PCS NPs as an
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antioxidant agent. Here, our nanodesign which facilitate the simultaneous presence of two highly
sustainably resourced antioxidants namely EA and CS results in a highly synergistic action of EA@PCS
NPs. Before applying the system in cells, we performed drug release studies and free radical scavenging
assays to examine the mechanism of drug release from EA@PCS and to estimate its radical scavenging
efficacy23, 104-106.
2.4.1. Free radical scavenging activity using DPPH assay
We conducted the DPPH assay to analyze the capability of EA@PCS to quench free radicals
(in the test tubes before moving to cells) and the possible synergistic effects due to the presence of EA
and CS107-110. At 60 µg/mL the scavenging abilities of EA, EA@PCS and CS against DPPH radicals
were calculated to be 91.2 %, 62.52% and 49.80%, respectively. Our result shows that EA@PCS
displayed considerable antioxidant activity against DPPH radicals (Figure 8 C). The quenching of
DPPH radical happens exclusively through a hydrogen transfer mechanism. Hence, the availability of
free hydroxyl and amine groups can significantly influence the performance. While EA has hydroxyl
(two at meta position and two at para position), the bonding involved in the formation of EA@PCS
could moderately reduce the availability of free functional groups. Hence, the slightly enhanced activity
displayed by EA is understandable. But EA is a known anti-cancerous agent and can have potential
cytotoxic effects at higher concentrations. The data (Figure 9 A & B), as expected, showed significant
cytotoxicity for EA at 60 µg/mL (~ 15 % cell death). The study points to the importance of
encapsulating EA in a more bio-compatible vehicle (such as PCS) and delivering it in smaller doses to
benefit from its antioxidant properties and mitigate cytotoxic effects.
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A

B
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Figure 8: Drug release profile (A) and DPPH radical scavenging activity of EA (B), EA@PCS (C)
and CS (D). Reproduced with permission from Ref 95.

After studying the drug release profile and establishing the free radical scavenging ability of the
nanohybrid, in vitro studies were carried out. Our in vitro studies included cytotoxicity, apoptosis,
DCFH-DA, and Rhodamine123 assays.
2.4.2. Cytotoxicity and Mitigation of RT-induced cell death
Our preliminary DPPH assay indicated excellent antioxidant properties for EA@PCS at 60
µg/mL leading to mitigation of free radicals (65.8 %) (Figure 9 C). Hence, we started with an initial
dose of EA@PCS at 60 µg/mL for in vitro studies. Before employing the dosage of the formulated drug
(60 µg/mL from DPPH assay), evaluating its cytotoxicity aspect and ensuring its biocompatibility is
critical. Cytotoxicity studies confirmed that EA@PCS NPs at 60 µg/mL has minimal cytotoxicity as
indicated by more than 90% cell viability upon exposure. Hence, 60 µg/mL of EA @PCS NPs was
selected as the optimal dosage for testing its capability to mitigate rotenone -induced oxidative stress
in the cells.
After establishing the cytotoxicity profile of EA@PCS we compared its biocompatibility with
other constituents at 60 µg/mL (Figure 9A). Figure 9 (A and B) shows the impact of EA, CS and
EA@PCS on rotenone mediated cell death87, 111-113. EA alone is able to attenuate RT-induced cell-death
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from ~50% at the applied RT concentration (50 µM ) to 43%. The antioxidant nature of CS is also
effective in mitigating RT-induced cell death to 30%. While this may be somewhat surprising, it is to
be noted that EA itself is somewhat cytotoxic relative to CS (comparison of Bar 7 with 5) which
explains the antioxidant potential of each candidate. Importantly, the application of EA@PCS against
rotenone-mediated cytotoxicity was more effective against that of either EA alone or CS alone against
the same RT concentration tested (23.5 % (EA@PCS), 39.8 % (EA) and 30.67 % (CS)). This reflects
the synergistic effect of EA and CS (PEG is inert). As previously discussed, the presence of CS mitigates
the cytotoxicity of EA and introduces synergy 84, 89, 90. The results suggest that EA entrapped in chitosanbased nanoparticle system can serve as a better protecting agent against rotenone insult than EA alone.
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Figure 9: Cytotoxicity of various compounds and rescue of cells from rotenone induced cell death in
SH-SY5Y cell by EA and EA@PCS (A), and (B) Hoechst-PI dual staining images of (i)
untreated cells, (ii) vehicle, (iii) EA@PCS, (iv) EA@PCS + RT, (v) EA, (vi) EA + RT,
(vii) RT (50 µM) and (viii) Hydrogen peroxide (positive control). Statistical significance
compared with untreated is illustrated as P-value which is <0.05. Reproduced with
permission from Ref 95.

2.4.3. Effect of EA@PCS on ROS production in RT treated cells and Measurement of
Mitochondrial Membrane Potential using Rh 123 dye

Elevated levels of intracellular ROS linked to disruption of mitochondrial membrane potential
(MMP) can be used as an indicator for ROS activity. Hence, we studied the impact of EA@PCS and
EA on the level of ROS upon rotenone insult by measuring the level of ROS inside the cells and
variation in MMP87, 111-113.
Intracellular ROS generation was measured by staining cells with DCFH-DA fluorescent probe.
Fluorescence intensity was monitored using a Fluoroskan Ascent Fluorescence CF system and the
fluorescence intensity was measured at 485/530 system. DCFH-DA enters the cell via simple diffusion
and is hydrolyzed to DCFH by intracellular acetylase enzyme. The non-fluorescent part, viz. DCFH,
when in contact with Reactive Oxygen Species gets oxidized into DCF resulting in the generation of a
green fluorescence. The fluorescence intensity obtained is directly correlated with the amount of ROS
inside the cells. Enhanced fluorescence upon dye binding is an indication of elevated ROS level inside
the cells while reduced or no fluorescence (compared to control) demonstrates alleviation in the level
of ROS. Rotenone treated cells (without the nanohybrid treatment) showed enhanced green
fluorescence indicating presence of oxidative stress inside the cells. However, pretreatment of cells
with EA@PCS and EA showed reduction in the levels of ROS as evident by reduced florescence
intensity. This could be attributed to the rescue of the cells by scavenging the ROS and mitigation of
the oxidative stress, induced by RT (Figure 10 A and B). The effect was more significant in case of
EA@PCS owing to the synergistic antioxidant activity of the nanoparticulate system.
Further, the ROS scavenging capability and its impact on oxidative stress in cells were also
studied by monitoring MMP. Rhodamine 123 dye is a non-toxic, cell-permeant, green fluorescent
cationic dye which is readily internalized by the mitochondria of the cell. The dye can be used to assay
the electrochemical potential across the mitochondrial membrane in cells undergoing apoptosis. The
incorporation of Rh 123 is dependent on the maintenance of the mitochondrial membrane potential and
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dissipation of the membrane potential is indicated by reduction in the green fluorescence. Fluorescence
intensity was monitored using a Fluoroskan Ascent Fluorescence CF system and the fluorescence
intensity was measured at 485/530 system. As evident from Figure 10 C and D, an increase in mean
percentage of depolarization and membrane permeability was observed on exposure to RT indicated by
reduced green fluorescence (which indicates the involvement of mitochondrial pathway in apoptosis).
However, cells pretreated with EA and EA@PCS prior to rotenone exposure shows green fluorescence
(similar to the negative control) pointing towards the rescue of the cell from the RT stress. The rescue
is attributed to the retention of polarized state of mitochondria (evinced from green fluorescence
compared to RT). Here again, the results were more pronounced in case of EA@PCS compared to free
EA.
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Figure 10: Effect of EA@PCS and EA on ROS scavenging ability (A &B) where B is (i) Untreated
cells, (ii) EA + RT cells, (iii) EA@PCS + RT and (iv) RT; Effect on Mitochondrial
Membrane Potential upon RT insult to SH-SY5Y cells (C&D) where D stands for (i)
Untreated cells, (ii) EA + RT cells, (iii) EA@PCS + RT and (iv) RT. Statistical
significance compared with untreated is illustrated as P-value which is
<0.05. Reproduced with permission from Ref 95.

2.4.4. Investigating the prophylactic activity of EA@PCS
The prevention of oxidative stress by EA@PCS can be due to its prophylactic activity via the
interaction between RT and EA@PCS and subsequent physisorption of RT on the surface. Once
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attached on the nanosystem, RT may not be able to bind to the complex I of mitochondria and induce
oxidative stress. Therefore, to study the feasibility of an adsorption of RT on the surface of EA@PCS
nanoparticles, we employed FT-IR and UV/Vis spectroscopy114-123. Figure 11 A indicates interaction
between EA@PCS and RT. The FTIR spectrum of RT shows absorption bands at 3,080 cm−1 which
corresponds to the aromatic C–H stretching, band at 2,972 cm−1 corresponds to the symmetric
stretching of terminal vinyl CH2 and absorption band at 2,938 and 2,913 cm−1 corresponding to the
aliphatic C–H stretching 47. Moreover, absorption bands at 1,674 cm−1 , 1,611 cm−1 and 1,514 cm−1
corresponding to C=O stretching of dihydro-γ-pyrone system, and aromatic C═C skeletal vibrations
were also observed 124, 125. Absorption bands at 1,352 and 1,303 cm−1 corresponds to the C–H bending
and C–O stretching of methoxy groups of dihydrobenzopyran system whereas 1,267 cm−1 and 1,233
cm−1 corresponds to C–O–C asymmetric stretching of aryl ethers. In-plane bending aromatic C-H was
124-126
also observed at 1,090 cm−1
. In EA@PCS-RT spectra, the intensity of absorbance band at 2,972

cm−1 was observed to be sharper than EA@PCS alone suggesting possible insertion of hydrophobic
groups at C2 of CS of EA@PCS

124-126

. Moreover, the EA@PCS-RT combination showed peaks at

1,674 cm−1 , 1,611 cm−1 (C=O stretching of dihydro-γ-pyrone system) and 1,514 cm−1 (aromatic
C═C skeletal vibrations) which are characteristics features of rotenone. The enhanced absorption band
at 1303 cm−1, 1,267 cm−1 and 1,233 cm−1 in EA@PCS-RT (compared to RT) and reduced band
intensity between 3000 to 3400 cm−1 and 1645 cm−1 (compared to EA@PCS) corresponds to possible
hydrogen bonding between hydroxyl and amine groups of EA@PCS with complementary oxygenated
and dehydrated heterocyclic rings of rotenone (dihydro-γ-pyrone, dihydro-benzopyran, and
dihydrobenzo-furan) 124-126. Moreover, the absorption band at 1087 cm−1 in EA@PCS-RT corresponds
to the -C-O stretch of the primary alcoholic group of CS in EA@PCS thus conforming possible
adsorption of RT by EA@PCS nanoensemble 98-103, 124-126. Hence the nanohybrid surface comprised of
chitosan can strongly interact with RT resulting in the adsorption. The interaction between RT and
EA@PCS was verified in the solution phase as well. The UV/Vis spectra (Figure 11 B) also suggest the
interaction between EA@PCS and RT in solution. The UV/Vis absorption spectrum of EA@PCS
showed two prominent features at 254 nm (corresponding to n-σ* transition) and a shoulder at 360 (due
n to p* transition) in EA. The EA@PCS sample incubated with RT showed additional features at 235
nm (corresponding to n-σ* transition of RT) and at 298 nm (due to n to p* transition of RT) indicating
the interaction and anchoring of RT in solution phase. Thus, the FT-IR and UV/VIS results points
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towards the adsorption of RT onto EA@PCS and possible prophylactic activity. Hence, the rescue from
the RT insult in cell studies observed is potentially through a prophylactic activity of EA@PCS.

(B)

(A)

Wavenumber (cm-1)

Wavelength (nm)
(nm)

Figure 11: FT-IR spectra of EA@PCS, RT and EA@PCS-RT mixture (A). UV/VIS spectra of
EA@PCS, RT and EA@PCS-RT mixture (B). Reproduced with permission from Ref 95.

3. PROPOSED MECHANISM OF ACTION OF EA@PCS NPS
We hypothesize that EA@PCS functions via a protective (prophylactic) route. Figure 12 A and
B is the representation of cells without stress and cell under stress upon RT exposure. As can be seen
(Figure 12 B), rotenone, owing to its small and hydrophobic structure, penetrates inside the cell and
binds to the Complex I at the ubiquitin binding site. The binding of RT with complex I prohibits the
transport of electron generated upon NADH oxidation. The inhibition of electron transfer will disturb
the electrochemical gradient which in turn effects the mitochondrial membrane potential. The generated
electrons that do not get correctly transported will then interact with the oxygen molecule inside the
mitochondria producing superoxide radicals and other ROS. The elevation in the levels of ROS in the
mitochondrial matrix onsets oxidative stress thus signaling cell death via apoptosis. Our FTIR and
UV/Vis data (Figure 12 A and B) suggests interaction between EA@PCS and RT pointing towards the
preventive action of the EA@PCS (Figure 12 C). Here, it is hypothesized to inhibit formation of ROS
by directly binding to the RT and not allowing RT bind to the Complex I of the electron transport chain.
The second possible mechanism through which EA@PCS rescues the cell (Figure 12 D) involves
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scavenging free radicals upon inhibition of Complex I of ETC by RT. Both CS and EA are well-known
antioxidants and can scavenge free radicals.

(A)

(C)

(B)

(D)
EA@PCS

Figure 12: Schematic representation of the proposed mechanism of action of EA@PCS showing cell
under normal conditions (A), under stress induced by RT (B), and rescue action of
EA@PCS (C & D). Reproduced with permission from Ref 95.
4. CONCLUSION
In this study, we have synthesized EA-loaded PCS nanoparticles and successfully implemented
it as a preventive agent for rotenone-induced oxidative stress in neuronal cell lines for the first time.
Although EA and CS are well-known antioxidants, the synergistic radical scavenging ability of the
nanoensemble is not yet studied. Our results emphasize that the encapsulation of the EA in CS-based
nanoensemble results in mitigation of the possible toxic effects of the parent drug. Finally, we propose
that EA@PCS could act as a neuroprotectant by acting as a prophylactic nanosystem against
neurotoxin, RT-induced oxidative stress which is reported to result in the onset of Parkinson's disease.
The prophylactic activity is due to the selection of the carrier components (i.e., chitosan) with reported
affinity to the causative species (i.e., rotenone). The concepts presented and the mechanisms proposed
are expected to trigger more research and open-up new avenues to design preventives and therapeutics
from sustainable resources.
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5. MATERIALS AND METHODS
5.1.Materials
All reagents were commercially sourced as follows: Ellagic acid (Sigma–Aldrich, USA),
dimethyl sulfoxide (DMSO) (Fisher Chemical, USA), sodium tripolyphosphate (Sigma-Aldrich, USA),
Polyethylene glycol 400 (PEG 400) (Merck KGA, Germany), Chitosan (>75% deacetylated, Low
molecular weight) (Sigma-Aldrich, USA), Rotenone (Sigma-Aldrich, USA), Acetic acid, Glacial
(Fisher Chemical, USA), and methanol (high performance liquid chromatography grade) (Fisher
Chemical, USA),Annexin V- FITC apoptosis kit (Beckman Coutler, Brea, CA, USA), Hoechst 33342
fluorescent stain (Invitrogen, Carlsbad, CA, USA), propidium iodide (PI) (Invitrogen, Eugene, OR,
USA), Fetal Bovine Serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA), and a human
neuroblastoma cell line SH-SY5Y (ATCC, Manassas, VA, USA). All reagents were of analytical grade
and were used without further purification.
5.2.Preparation of Ellagic acid loaded peg-chitosan nanoparticles (EA@PCS)
Chitosan nanoparticles were prepared using sodium tripolyphosphate (TPP) by ionotropic
gelation method with slight modifications 73. Chitosan solution 0.175% (w/v) was prepared in 1% (v/v)
aqueous acetic acid at 35 oC temperature and was kept for stirring overnight. Sodium tripolyphosphate
(TPP) 0.1% (w/v) was added dropwise to the chitosan solution and the solution was stirred at 1000 rpm
for 10 minutes. PEG-400 1% (v/v) was added to the solution in dropwise fashion and stirred for 30
mins or until the solution was homogenous. The pH of solution was adjusted to 5.2 with the help of 1
M NaOH. The solution was centrifuged at 14, 534 *g (Sorvall RC-5B refrigerated super-speed
centrifuge, USA) for 90 minutes at 4oC to pelletize chitosan nanoparticles. The supernatant was
discarded, and the pellet was washed thrice with deionized water. Finally, ultra-sonication was
performed using a probe sonicator (Branson Sonifier 450, USA) in an ice bath for 10 minutes at 30%
amplitude. The obtained suspension was then immediately freeze-dried at -80 oC for 36 h using
lyophilizer (Labconco, USA). The nanoparticles were then stored at 4 oC for further analysis. For
preparation of Ellagic acid-loaded peg-coated chitosan nanoparticles (EA@PCS), 0.3 mg/mL of Ellagic
acid in DMSO was added to the chitosan solution along with sodium tripolyphosphate (TPP) and PEG400. After stirring at 500 rpm for 60 mins under ambient conditions, the solution was centrifuged at
14, 534 *g for 90 minutes and then the solution was subjected to ultra-sonication in an ice-bath for 10
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minutes at 30 % amplitude. The sample was then freeze-dried and later stored at 4 oC for further
analysis94, 127-129.
5.3.Characterization
The UV/VIS spectra of EA and EA@PCS nanoparticles was obtained using an Evolution 201
spectrophotometer (Thermo Fisher Scientific) by measuring maximum absorbance at 360 nm. HPLC
separation of the material was performed over a total run time of 140 minutes. The mobile phase used
was 0.1 % TFA water and a gradient of Acetonitrile (80%) at a flow rate of 0.500 mL/min with % B at
t0 = 0 %, t10 = 0 %, t110 = 100 % and t140 = 0 % was established. The column temperature was maintained
at 23.5oC with a sample volume injection of 125 µL. Since, the drug was observed to absorb at 360 nm
(UV/VIS study) therefore, 360 nm was set as detector wavelength for HPLC analysis. Particle size,
polydispersity index and surface charge was analyzed using a Malvern Zetasizer ZS 90 (Malvern
Panalytical Ltd., Malvern, UK).
The surface morphology of EA@PCS samples was determined using Scanning Electron
Microscope (JEOL JSM-7500F Scanning Electron Microscope, Peabody, USA). Samples were crushed
gently to a fine powder, whenever necessary, using a clean mortar and pestle to avoid large flakes.
Further, powder samples were mounted on a stainless stub using double-sided carbon tape. Each sample
was coated with gold to make the sample conductive using a Denton Vacuum Desk II for 30 seconds.
Images were recorded at an accelerating voltage of 2kV and a probe current below 20 μA.
The morphology of the EA@PCS was analyzed using TEM (HITACHI HD-2300 A, Ultrathin
Film Evaluation System by Hitachi High Technologies America, Pleasanton, CA). The dispersion was
drop-casted on a copper grid (Ted Pella, Redding, CA) and dried overnight in a sterile fume hood. The
instrument was operated at 200kV and images were captured using Quartz PCI version 8 software in
TEM and SEM mode.
FTS 4000 attached with the microscope UMA 600 equipped with micro ATR with GE crystal
was used for obtaining the IR spectra of CS powder, TPP, EA, PCS, and EA@PCS. All the samples
were grounded to a fine powder prior to mounting on a GE crystal. The scanning range was from 4004000 cm-1.
X-ray diffractions were obtained for CS, PCS, EA and EA@PCS using PAN analytical's X-ray
diffractometer equipped with X'Celerator high speed detector (PAN analytical's Xpert Pro Tokyo,
Japan) in a BB004x flat mode. The samples were grounded to a fine powder texture. Powdered samples
were mounted in an aluminum sample holder and packed uniformly using a glass slide. PXRD patterns
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of the samples were measured by Cu Kα source of 45 kV and a current of 40 mA. X-ray scattering
measurements were obtained with continuous scanning mode over a 2θ range of 5° to 40° for 15
minutes. Match! Software was used to obtain the data after the scan.
5.4.Entrapment Efficiency (%) and Drug release studies
The drug-loaded nanoparticles were dispersed in deionized water and sonicated using a probe
sonicator at an amplitude of 30% for 20 minutes. For direct determination of EA@PCS entrapment
efficiency, the dispersion was transferred to an ultracentrifuge tube and centrifuged at 3,634*g for 60
minutes. Later the absorbance of the supernatant was recorded at 360 nm using double beam UV visible
spectrometer (GENESYS 10S). The entrapment-efficiency of EA@PCS was calculated as follows:
EE % = (Drug Total-Drug free) / Drug Total × 100

(i)

Release study of Ellagic acid was carried out by using membrane dialysis method in PBS medium
(pH 7.4). A 10 mg/mL suspension of NPs was resuspended in dialysis membrane. About 5 mL of the
obtained suspension was then placed in a membrane bag which was later placed in 30 mL PBS under
magnetic stirring at 120 rpm at 37oC. Subsequently, at predetermined time periods (1, 2, 3, 4, 5, 6, 7, 8, 12,
24 hrs) the release media was replaced with fresh media. The collected sample was analyzed quantitatively
via double beam UV visible spectrometer (GENESYS 10S) at 360 nm 73, 130-136.
5.5.DPPH Radical Scavenging Activity Assay
The antioxidant activity of EA alone and EA@PCS NPs was determined using DPPH (2,2diphenyl-1-picrylhydrazyl) free radical scavenging assay. The stock solution was prepared by
dissolving 24 mg DPPH powder in 100 mL methanol. Later, the solution was refrigerated until further
use. Next 160 µL of different concentrations of EA@PCS were mixed with 2 mL of methanolic DPPH
solution in a cuvette. On mixing, a color change from violet to pale yellow was observed indicating
formation of stable non-radical form of DPPH. The absorbance at 517 nm was then measured for the
sample extracts. The percentage of DPPH free radical quenching activity was determined using the
following equation:
Antioxidant activity (%) = (AbsDPPH – AbsExtract) × 100/ AbsDPPH

(ii)

where AbsDPPH is the absorbance value at 517 nm of the methanolic DPPH solution and AbsExtract is the
absorbance for the sample extracts at 517 nm. Each sample was analyzed three times108, 110.
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5.6.Cell culture
SH-SY5Y cells (adherent and non-differentiated) were kept frozen in liquid nitrogen until
passaged. The cells were grown in Dulbecco's modified Eagle's medium and Hans's F12 media mixture
(1:1) comprising of 10% FBS (v/v) supplemented with 1% (v/v) penicillin-streptomycin and incubated
at 37 °C in an atmosphere of 5% carbon dioxide. Media was changed several times per week and cells
were passaged once per week. Trypsin-EDTA 0.25% (1×) was used to detach cells from the culture
surface when needed.
5.6.1. Cell death study using Cytotoxicity
For cytotoxicity, SH-SY5Y cells were first cultured in a 96-well plates at a density of 10,000
cells per well followed by incubation for 24 hours to allow cellular attachment to the plate surface.
Hydrogen-peroxide-treated cells served as a positive control and untreated cells as a negative control.
Subsequently, cells were treated with different concentrations of EA and EA@PCS to determine the
least cytotoxic concentrations. Later, cells were pre-incubated with selected EA and EA@PCS
concentrations 6 hours prior to rotenone exposure ( 50 µM) followed by 24 hours incubation. 2 µL of
1 mg/mL of PI/Hoechst 33342 was added to each well and then the well-plate was covered with
aluminum foil and kept in incubator at 37oC for one hour prior to imaging 74, 87, 137. The images were
captured using a Bioimager system (BD Biosciences Rockville, Montgomery, MD, USA). Four images
were taken per well using a 10× objective lens. Subsequently, BD AttoVision v1.6.2 software (BD
Biosciences Rockville, Montgomery, MD, USA) was used to determine the percentage cell death per
well.
5.6.2. Measuring ROS using DCFH-DA assay
Cells were cultured in a 96-well plate at a density of 10,000 cells/well. This was followed by
incubation for 24 h to allow cellular attachment to the plate surface. Subsequently, cells were treated
with EA and EA@PCS followed by rotenone treatment and further incubation for 18 hours. Later, 2 uL
of 10 µM DCFH-DA was added to each well. After about 15 minutes of incubation at 37oC, cells were
rinsed with PBS buffer thrice. Later, fluorescence intensity was monitored using a Fluoroskan Ascent
Fluorescence CF system and the intensity was measured at 485/530 system74, 87.
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5.6.3. Measurement of Mitochondrial Membrane Potential (MMP)using Rhodamine 123
assay
To study the effect of rotenone on mitochondrial functions, Rh 123, a cationic dye was used. It
involved measuring Mitochondrial Membrane Potential in intact cells by monitoring fluorescence
intensity. Briefly, cells were cultured in 96-well plates followed by incubation for 18 h to allow cellular
attachment to the plate surface. Subsequently, cells were pre-incubated with EA and EA@PCS six hours
prior to rotenone exposure followed by 24 hours incubation. Later, the cells were incubated with
rhodamine 123 dye at 37 °C for 30 min. Finally, the MMP was analyzed quantitatively using a
Fluoroskan Ascent Fluorescence CF system and the fluorescence intensity was measured at 485/530
nm74, 87.
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6. SUPPORTING INFORMATION

(C)

(D)

Figure 13(Figure S1): UV-Vis spectra of CS, PCS, TPP and PEG (A); SEM images of CS NPs and
PCS NPs in the same order (B) UV/VIS spectra of EA and EA@PCS NPs (C) and
HPLC chromatogram of EA and EA@PCS NPs (D). Reproduced with permission from
Ref 95.

Figure 14(Figure S2): DSC curve of CS NPs, EA, PCS NPs (PC), TPP and EA@PCS NPs (PCE).
Reproduced with permission from Ref 95.
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Figure 15 (Figure S3): AFM image of EA@PCS NPs showing elliptical nanoparticles with an
average size of 200 nm. Reproduced with permission from Ref 95.

Figure 16 (Figure S4):
Drug release profile
of nanohybrid before and after wash. Reproduced with permission from Ref 95.
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Figure 17 (Figure S 5): TEM images of EA@PCS at pH (A) 5.5 and pH (B) 7.5 and effect of pH on
zeta potential (C). Reproduced with permission from Ref 95.
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Chapter 3: Multi-Functional Carbon quantum dots prevent soluble-to-toxic transformation of
amyloid and oxidative stress
ABSTRACT
Carbon quantum dots (CQDs), depending on their surface functionalization, have found utility across
a number of biological applications. Here, we demonstrate that individual CQDs can serve multifunctional roles, which is a key requisite for the development of drugs for neurodegenerative disorders
such as Parkinson’s disease (PD). Na-citrate-, Phenylboronic acid-, and 4-aminophenylboronic acidderived Carbon quantum dots (CQDs) were evaluated for their ability to intervene in amyloid-forming
trajectories and restore intracellular homeostasis under oxidative stress. While all three CQDs were
able to prevent the soluble-monomer to mature-fibril conversion of Hen-egg white lysozyme (HEWL),
Na-citrate and 4-aminophenylboronic acid derived CQDs were also able to scavenge Reactive oxygen
species (ROS) when exposed to broad spectrum free radical generators. Furthermore, Na-citrate and 4aminophenylboronic acid CQDs pre-incubated in neuroblastoma-derived SHSY-5Y cell line were able
to rescue it from rotenone (neurotoxicant)-induced cell-death while demonstrating no difference in
cytotoxicity up to 120 µg/mL (compared to untreated controls). The CQDs were also able to restitute
cells from rotenone-elicited apoptosis and oxidative stress. Together, these results suggest that CQDs
can serve as a one-pot solution for the multifactorial diseases such as PD by serving as a
neuroprotectant. Importantly, the use of CQDs as multi-factorial interventional agents represent a
sustainable mechanism by which to advance biomedicine.
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1. INTRODUCTION
Parkinson’s disease (PD) is the second most common, age-related, progressive
neurodegenerative disorder affecting more than 6 million people around the world

8, 138

. It is an

idiopathic motor system disorder with no treatment present that can effectively prevent the progression
of the disease. The criteria for the diagnosis of PD includes progressive loss of dopaminergic neurons
in the substantia nigra pars compacta along with the presence of Lewy pathology. The various molecular
outcomes associated with the disease includes proteopathy, onset of oxidative stress, mitochondrial
dysfunction, metal ion dyshomeostasis, aberrant axonal transport and chronic inflammation 1, 8, 138. In
this work, proteopathy using lysozyme as a model protein and oxidative stress resulting from rotenone
insult are regarded as target for halting the progression of the disease using a relatively novel form of
sustainable, carbon nano materials, viz Carbon quantum dots.
Carbon quantum dots (CQDs) have been sourced from a number of carbon-containing precursors
including wastepaper, fruit peel, amino acids, organic acids, and algae

139-143

. Their ease of synthesis

via a bottom-up approach involving hydrothermal polymerization and carbonization of the
aforementioned exemplar carbon precursors qualifies them as a green-chemistry derived carbon nano
materials (CNMs) manufactured using sustainable resources and sustainable chemistry. CQDs have
also found applications in electrocatalysis, in optronic, theranostic, sensing and biomedicine 144-159.
Within the biomedical realm, depending upon the nature of the CQDs, there have been
applications in bioimaging, drug delivery, gene and, cancer therapy 140, 141, 148, 154, 157. For example, sp2
hybridization rich CQDs serve as free radical scavengers144, 146, 148. Se-sulfur doped CQDs from citric
acid also possess radical scavenging activity as evidenced via the DPPH assay wherein they were able
to “eliminate” both hydroxyl and superoxide radicals. CQDs were able to ameliorate the fibrillation
and cytotoxicity of human islet amyloid polypeptide. High-oxygen-content CQDs demonstrated
excellent efficiency in the inhibition of human insulin aggregation149,

150

. Graphene quantum dots

(GQDs), which are also carbon nanomaterials, prevent α-synucleinopathy and intervene in the onset of
Parkinson’s disease157.
In each of these applications, CQDs were functionalized by surface-modification of the carbon
core for tailored applications and optimization therein. From the examples listed, it is clear that CQD
use is highly advantageous over the use of small molecules for the same purpose. Unlike smallmolecules, it allows for tuning of the architectures and the development of second-generation CQDs
that have been functionally optimized via Structure-Activity-Relationship analyses160, 161.
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Here, for the first time, we have investigated whether a single CQD can perform multiple
functions related to the onset of neurodegenerative pathologies. Previous reports have demonstrated
that protein aggregation and oxidative stress interact to exacerbate the others’ impact to provoke
neuronal injury, demise, and initiate neurodegenerative disorders1, 8, 138. We demonstrate that CQDs can
target both the soluble-to-toxic transformation of amyloids (leading to aggregation) and mitigate
elevated levels of reactive oxygen species. Since each of these aberrant cellular events influences the
other, as aforementioned, the dual nature of the CQD has even more impact than the sum of the
individual effects. Towards this objective, CQDs derived from organic acids were characterized and
assayed to investigate their ability to intervene in fibril formation, and act as an antioxidant to mitigate
oxidative stress inside the neurons. The synthesis of CQDs did not require harsh experimental
conditions such as organic solvents as water was used as the solvent. Hence, in terms of yield, quantity
of product produced and absence of organic solvents, the CQDs followed a green synthesis approach
showing that they are environmentally friendly and sustainable carbon nanomaterials.
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2. RESULTS
2.1. Physico-chemical characterization of as-synthesized CQDs
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Figure 18: Characterization of CQDs: (A-C) are TEM images of Na-citrate, phenylboronic acid, and
4-aminophenylboronic acid CQDs. (D) depicts the absorption spectrum of CQDs 1-3. (E
and F) are the IR and Raman spectra of Na-citrate, phenylboronic acid, and 4aminophenylboronic acid CQDs, respectively while (G-I) are their excitation-dependent
emission spectra. Reproduced with permission from Ref162.
CQDs were synthesized from Na-citrate (CQD 1), phenylboronic acid (CQD 2), and 4aminophenylboronic acid (CQD 3) CQDs as the carbon-containing precursor. The CQDs ranged in size
and varied in size-distribution. Na-citrate CQD exhibited sizes ranging from 2-9 nm with significant
fractions possessing sizes between 3-8 nm that were spherical in shape (Fig 18A). By contrast, the
phenylboronic acid CQDs were larger with sizes ranging from 12-22 nm. Akin to Na-citrate CQDs, the
phenylboronic acid CQDs sizes were found to be broadly distributed within this range and were
spherical in shape (Fig 18B). Finally, while 4-aminophenylboronic acid CQDs ranged in size between
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5 and 13 nm (Fig 18C), a significant fraction of the CQDs had sizes that ranged between 8-11 nms with
the population distribution falling off on either side and were quasi-spherical shaped.
The UV-Vis spectra of the CQD’s revealed remarkable differences across the CQDs (Fig
18D). Na-citrate CQDs displayed a shoulder at 280 nm and a peak at 350 nm suggesting sp2
hybridization and resonance-capable moieties (aromatics)107, 163. phenylboronic acid CQDs displayed
weak absorption with a relatively broad peak centered at ~ 290 nm. The gradual tapering of absorbance
with increasing wavelengths may suggest the presence of moieties that are capable of resonance
stabilization. However, the weak absorption is indicative of limited concentration of the architectures
corresponding to their excitation maximums. Unlike the phenylboronic acid CQDs the 4aminophenylboronic acid CQDs CQD demonstrated a prominent peak at 280 nm. This is suggestive of
the presence of a rich concentration of aromatic (sp2 hybridized) moieties107, 163. The tapering of the
UV spectrum at wavelengths beyond 280 nm is similar to that observed with phenylboronic acid CQDs
except for a slight inflexion at ~ 330 nm.
An examination of the IR spectrum of Na-citrate, phenylboronic acid and 4aminophenylboronic acid CQDs show typical signatures reflective of carbonyl carbons, carboxylic
groups, and aliphatic moieties (Fig 18E). Asymmetric ring stretching and the deformation of the
aromatic ring could also be discerned. At higher wavenumbers, both the hydroxyl and amino functional
groups are observed. The loss in the sharpness of the peaks of the Na-citrate CQDs potentially indicates
the presence of overlapping modes that are hallmarks of the complexity of the CQD. The IR spectrum
of phenylboronic acid CQDs shows the peaks remain relatively sharp suggesting that the
functionalization was relatively low in yield. It could also indicate the presence of unreacted starting
material. By contrast, the IR spectrum of 4-aminophenylboronic acid CQDs also lacked the presence
of sharp peaks which reflects the presence of multiple overlapping moieties.
The Raman spectra of Na-citrate, phenylboronic acid and 4-aminophenylboronic acid CQDs
are shown in Fig 18F. The three CQDs display the presence of “D” band at ~1360 cm-1 and “G” band
at ~ 1580 cm-1. The D band in the CQDs is a disorder-induced band which represents presence of
disorder on the edges in the form of sp3 hybridized carbon, functional groups, and surface states on the
surface of the as-synthesized CQDs. The presence of G band arises due to the in-plane C-C vibrations
of conjugated sp2 hybridized carbon atoms164, 165. The increase in the broadness of D band can be
attributed to the increase in the amount of sp3 hybridized content of carbon-to-carbon bond, carbon to
oxygen bond, carbon to nitrogen bond and hydroxyl bonds. The D and G bands corresponds to the
successful synthesis of CQDs164, 165.
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The excitation dependent emission spectrum is displayed in Figs 18 G, H, I. The results show
a red shift in the emission maximum of all three CQDs (Na-citrate, phenylboronic acid and 4aminophenylboronic acid CQDs) as a function of increasing excitation. This is a phenomenon that has
been ascribed to the differences in size, presence of heterogeneous chemical architectures constituting
CQDs and to the presence of defects within the structure165. All three CQDs demonstrate consistency
with such previous findings. The red shifted maxima in the visible region indicate a range of
wavelengths that the CQDs can be imaged at (as discussed later).
2.2. Impact of CQDs on the soluble-to-toxic transformation of amyloid protein

Fragmentation

Secondary
neucleation

Native protein

Misfolded protein

Oligomers

Protofibrils

Depolymerization
Fibrils

Figure 19: Schematic representation of amyloid misfolding and aggregation: Fibril forming trajectory
showing transformation of soluble monomeric species to insoluble, cross- β rich fibrils.
The scale bar in the TEM image is 500 nm. Reproduced with permission from Ref162.
The critical role of amyloid proteins in the onset of various neurodegenerative diseases is well
established1. In the case of intrinsically disordered proteins including amyloid proteins, the fibrillation
process follows a sigmoidal trend which consists of a lag phase, an elongation phase, and a saturation
phase (Figure 19). The monomeric protein precursor can aggregate forming fibrils by a nucleationgrowth mechanism. This soluble-monomer to insoluble-fibril transition involves formation of
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oligomers (dimers, tetramers, hexamers, and dodecamers) and protofibrils in the protein misfolding
landscape. The oligomeric species can be soluble or insoluble depending on their β -sheet content and
order in the nucleation phase. The higher-order oligomeric species have a more β -sheet rich secondary
structure and are comparatively less soluble. During the fibrillation process, in the nucleation phase,
the higher-order oligomeric species can assemble to form a nucleus which are kinetically most unstable
species that are formed before the rapid polymerization of intermediate species into fibrils. By contrast,
in the elongation phase, the filaments undergo an exponential growth until monomeric counterparts are
consumed. These fibrillar assemblies are an outcome of nucleation-extension growth process. Once the
fibrils with cross- β architecture are formed, they can undergo fragmentation event which can result in
formation of more fibrillar ends that can serve as a substrate for the formation of new fibrils.
Simultaneously, secondary nucleation can take place enhancing the rate of fibril formation (Figure 19).
The finally formed fibrils can then associate with each other to form intracellular inclusions which are
characteristics of PD1, 138.
CQDs that intervene in amyloid-forming trajectories are desirable to target protein misfolding
related disorders. The formation of oligomers and protofibrils is toxic to an organism159. These
intermediates act as seeds that promote the conversion of their soluble monomeric counterparts into
aggregates that eventually form insoluble fibrils. CQDs that prevent the formation of fibrils potentially
acts along the pathway at one or many of the constituents that eventually form fibrils.
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Figure 20: HEWL fibrillation inhibition assays: (A-C) ThT fluorescence assay to monitor the
prophylactic activity of our as-synthesized Na-citrate (CQD 1), phenylboronic acid
(CQD 2), and 4-aminophenylboronic acid (CQD 3) CQDs. HEWL fibril formation was
achieved after 8 hours of incubation and is evident by high ThT fluorescence. However,
HEWL monomers that were pre-incubated with 1mg and 5 mg/mL of Na-citrate,
phenylboronic acid, and 4-aminophenylboronic acid CQDs showed reduced or no ThT
fluorescence indicating fibrillation inhibition in the presence of Na-citrate,
phenylboronic acid, and 4-aminophenylboronic acid CQDs. (D-F) represents the CD
spectra of monomers alone, fibrils, CQDs, and CQDs with HEWL. As evident through
the graphs, the HEWL solutions pre-incubated with Na-citrate, phenylboronic acid, and
4-aminophenylboronic acid CQDs displayed reduced, or no beta-sheet structure indicate
fibrillation inhibition by our CQDs. Reproduced with permission from Ref162.
Figure 20 shows the impact of CQDs on the ability of lysozyme monomers to form fibrils 159.
In Fig 20 A-C, the presence of HEWL fibrils is detected by ThT as evidenced by a sharp increase in
fluorescence intensity upon addition of ThT to the solution containing fibrils (black curve). The
introduction of Na-citrate CQDs (1 mg/mL) (Fig 20A) to the fibril-forming solution resulted in a
diminution in the ThT fluorescence (green curve) relative to the untreated control. Incubation of
monomeric HEWL with 5 mg/mL of the aforementioned CQD’s resulted in a further attrition in the
formation of mature fibrils (purple curve). By contrast, the addition of phenylboronic acid CQDs at
5mg/mL (Fig 20B), and even 1 mg/mL, completely annihilated the ability of HEWL to form fibrils.
The ThT fluorescence was essentially flat suggesting the absence of any fibrils within the limits of
detection. Finally, the addition of 5 mg/ml of 4-aminophenylboronic acid CQDs (Fig 20C) had a similar
impact of HEWL fibrillation as phenylboronic acid CQDs. However, at 1mg/mL of 4aminophenylboronic acid CQDs, there was a slight inflection in the ThT fluorescence. This suggests
that 1mg/mL was not sufficient to eliminate the soluble-to-fibril transformation of HEWL. A
comparative analysis of the assays revealed that phenylboronic acid CQDs was the most efficient in
preventing the toxic-transformation of HEWL, followed by 4-aminophenylboronic acid CQDs.
To probe the mechanism by which CQDs prevent formation of HEWL fibrils, we probed the
CQD-dependent secondary structure of HEWL using circular dichroism (CD) (Fig 20 D-F). The CD
data reveal a dose-dependent attrition in the β-sheet content of HEWL. As the CQD concentration was
increased from 1mg/ml to 5 mg/ml, there was a total elimination of β-sheet structure by phenylboronic
acid CQDs (Fig 20E). The presence of Na-citrate, and 4-aminophenylboronic acid CQDs also resulted
in a high degree of reduction of β-sheet content in HEWL (Fig 20D and F). Our data reveals that the
presence of CQDs (Na-citrate, phenylboronic acid, and 4-aminophenylboronic acid CQDs) prevent the
formation of HEWL fibrils. Here, phenylboronic acid, and 4-aminophenylboronic acid CQDs were
found to be more efficient that Na-citrate CQDs.
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2.3. Determination of antioxidant potential of CQDs using DPPH and FRAP assays
There is growing evidence that accumulation of free radicals inside the cells induces gravest
of human diseases such as cancer and neurodegeneration. Free radicals are atoms or molecules that has
unpaired electrons, making them unstable. In order to become stable, these free radicals try to electronpair with biological macromolecules or oxidizable substrates such as protein, DNA, and lipids which
ultimately results in radical-induced cell damage. To overcome this oxidative stress-induced damage,
antioxidants/reductants are supplied to either delay or prevent the damage caused by oxidants either by
donating a hydrogen atom or by electron transfer. This section of the paper tests the antioxidant potential
of our as-synthesized CQDs using standard in test tube assays such as DPPH (2,2-diphenyl-1picrylhydrazyl) and FRAP (Ferrous Reducing Antioxidant Potential)108, 110.
We first screened the free radical scavenging capability of our Na-Citrate, phenylboronic acid,
and 4-aminophenylboronic acid CQDs using the DPPH assay. It is a widely used method to screen
antioxidants before transitioning to cell-based assays as it is rapid, simple, and inexpensive (Fig 21AC). This colorimetric assay is based on measuring the free radical scavenging capability of an
antioxidant by reducing the odd electron on nitrogen atom of diphenylpicryl hydrazyl (shows
absorbance at 517 nm) to diphenylpicryl hydrazine by donation of a hydrogen atom by an antioxidant.
This reduction of diphenylpicryl hydrazyl to diphenylpicryl hydrazine results in change of color of
solution from violet to yellow and a decrease in absorbance at 517 nm indicating neutralization of free
radical by a hydrogen donor108-110. In our experiments, Na-Citrate, and 4-aminophenylboronic acid
CQDs (Fig 18A and C) demonstrated a dose-dependent ability to scavenge free radicals by hydrogen
donation as demonstrated using the colorimetric output. Na-citrate CQDs appeared to be more efficient
that 4-aminophenylboronic acid CQDs at the same dose. Interestingly, phenylboronic acid CQDs (Fig
21B) did not show any radical scavenging ability in the range tested.
To independently verify these results, we examined the antioxidant power of our Na-citrate,
phenylboronic acid, and 4-aminophenylboronic acid CQDs using another simple and inexpensive assay
namely FRAP (Fig 21D-F). This assay is based on the ability of candidates to reduce Fe3+ to Fe2+ at
low pH where a colored ferrous-tripyridyltriazine complex is formed by reduction of ferrictripyridyltriazine complex107, 108. This transition results in formation of an intense blue colored solution
from a colorless solution with an absorption maximum observed at 593 nm. The FRAP data for
phenylboronic acid CQDs mirrored that obtained from the DPPH assay (Figure 18E). Essentially, there
was no impact of phenylboronic acid CQDs (between 0-100 µg/ml) on free radicals (determined via
the DPPH assay). As anticipated, both Na-citrate, and 4-aminophenylboronic acid CQDs demonstrated
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scavenging ability with the exception that 4-aminophenylboronic acid CQDs was found to be slightly
more effective than Na-citrate CQDs when examined by the FRAP assay (Fig 21D and F). Figure 21 G
and H shows the images of cuvette for the DPPH (Fig 21G) and FRAP (Fig 21H) assay after the CQDs
were introduced into the free radical solutions. As evident through absorption data (Fig 21A-F), the
images (Fig 21 G and H) also shows that although Na-citrate, and 4-aminophenylboronic acid CQDs
showed antioxidant potential, phenylboronic acid CQDs were not efficient enough in neutralizing the
free radicals in the solution.
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Figure 21: In-test tube antioxidant assays: (A-C) shows the free-radical scavenging capability of our
Na-citrate, phenylboronic acid, and 4-aminophenylboronic acid CQDs using the DPPH
assay. (E-G) represents the FRAP assay to determine the ability of our CQDs 1-3 to
reduce Fe3+ to Fe2+. (D and H) shows the image of cuvette for the DPPH and FRAP
assay before the readings using UV -Vis spectrophotometer was taken. Reproduced with
permission from Ref162.
2.4. Determination of cell viability and rescuing ability of CQDs in neuroblastoma cell line
insulted with rotenone
Reactive Oxygen Species (ROS) elevation across a number of pathologies including cancer,
asthma and chronic obstructive pulmonary disease, atherosclerosis, arthritis, ocular disease and
neurodegeneration1, 8, 138. For example, characteristic to neurodegenerative disorders is the corruption
of neurocellular machinery due to mitochondrial dysfunction and the resulting ROS stress. In
mitochondria, ROS such as hydrogen peroxide, hydroxyl radicals and superoxide radicals are produced
as part of the normal biochemical processes. However, in disease, the balance between production and
removal of ROS is disrupted. This is either due to a genetic mutation in certain enzymes (Superoxide
dismutase, Glutathione peroxidase, catalase) which are responsible for effectively neutralizing these
ROS or due to overexposure to environmental neurotoxins including pesticides such as rotenone, a
mitochondrial inhibitor. When elevated in level, hydroxyl radicals, superoxide and nitric oxide can
combine with each other to form peroxynitrite, which is a potent ring-nitrating agent that can chemically
modify Phe, Tyr, and Trp residues87,

111-113

. Nitric oxide itself can form S-nitroso derivatives of

glutathione and compromise the redox status of the cell. S-nitroso adducts being labile permit NO to
reach the lumen of the endoplasmic reticulum where they chemically mutate the catalytic cysteines of
the oxidoreductase chaperone protein disulfide isomerase (PDI)87, 111-113. SNO-PDI formation in turn
provokes the aggregation of amyloid proteins87, 111-113. It causes HSP70 overexpression, an increase in
the ubiquitinated debris and PARP cleavage.
Another hallmark of neurotoxicity leading to neurodegeneration is the triggering of apoptosis
and necrosis pathways87,

111-113

. Free radicals attack major biomolecules (proteins, DNA/RNA,

carbohydrates, and lipids) inside the cells. The polyunsaturated fatty acids (PUFA) composing the cell
membranes are one of the main target sites of these free radicals which then cause lipid peroxidation1,
8, 138

. The active byproduct of lipid peroxidation is an aldehyde that can quickly diffuse from the site of

the attack to other parts of the cell, eventually resulting in tissue damage and the onset of disease.
Hydroxyl radicals have been observed to react with the DNA resulting in the oxidative damage of the
sugar moiety of the oligonucleotides and the heterocyclic base moiety resulting in DNA strand breaks
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and generation of base-free sites in the DNA1, 8, 138. The outcome of such reactions is the generation of
impaired double-stranded DNA (dsDNA), which can induce mutagenesis, carcinogenesis, senescence,
etc. Furthermore, the free radicals in the form of activated oxygen species, in the presence of Fe2+ and
Cu2+, can induce oxidative damage to the proteins arising due to the modification of the amino acids,
forming peroxides and carbonyls1, 8, 138. Amino acids, such as proline, lysine, arginine, and histidine,
are the most sensitive to such oxidative damage. Such oxidative damage results in the generation of
oxidized proteins, which is highly correlated to various pathophysiological conditions such as
neurodegenerative diseases1, 8, 138. Another target of the free radicals is the powerhouse of the cell, viz.
the mitochondrion. Oxidative damage to mitochondria results in mitochondrial dysfunction which can
result in (i) reduced amount of energy to the affected cell, (ii) disruption of calcium homeostasis (an
essential secondary messenger inside the cell), (iii) collapse of the mitochondrial proton motive force,
(iv) reduced mitochondrial membrane potential, and (v) can also activate a cascade of signaling
pathways resulting in cell apoptosis (programmed cell death). This cascade of homeostasis-disrupting
events, initiated by redox imbalance, eventually results in the onset of the neurodegenerative phenotype
in cell lines. It onsets neuronal corruption and neuronal demise in vertebrates. Various small molecules
have been used as free-radical scavenging drugs including gallic acid, ellagic acid, Vit E, EGCG, and
curcumin. Their therapeutic efficacy and mechanism of action has been established. However,
limitations such as poor aqueous solubility, low permeability and toxicity at higher doses limits their
potential54-57, 62, 65.
Therefore, this section of the paper is dedicated to studying the effect of rotenone (cell stressor)
on neuroblastoma cells (SHSY-5Y) and how preincubation of cells with our CQDs protects them
against rotenone-elicited oxidative stress and apoptosis.
Based on the results from DPPH and FRAP assays, we exposed Na-citrate, and 4aminophenylboronic acid CQDs to a SHSY-5Y cell-line model of reactive oxygen species insult using
rotenone as the cell-stressor 64, 95, 166, 167. This neuroblastoma-derived cell line is an established standard
for studying the onset of the Parkinsonian phenotype87, 95, 111-113.
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Figure 22: Cell viability assays: (A) shows the cytotoxicity profile of Na-citrate, and 4aminophenylboronic acid CQDs in the concentration range 0-120 µg/mL. (B) shows the
confocal images of SHSY-5Y cells treated with Na-citrate, and 4-aminophenylboronic
acid CQDs at 500 µg/mL after 6 hours of incubation. UT stands for untreated cells.
Reproduced with permission from Ref162.
Figure 22 (A-B) shows the cytotoxicity profile of Na-citrate, and 4-aminophenylboronic acid
CQDs on the cell line. The data indicates that both CQDs essentially mimic untreated controls up to the
tested concentration of 120 µg/ml. Fig 22 B shows the confocal images of cells incubated with 500
µg/ml of Na-citrate, and 4-aminophenylboronic acid CQDs and as evident through the images, the
CQDs were not toxic to the cells.
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Figure 23: Cell-rescue assays: (A) represents the percentage of cell death upon introduction of
Rotenone (5 µM) and the rescue of cells from rotenone insult upon pre-incubation of
cells with Na-citrate, and 4-aminophenylboronic acid CQDs at different concentrations
prior to Rotenone insult; (B-C) Apoptosis and necrosis assays to ascertain the pathway
of cell death upon introduction of Rotenone (5 µM) and upon pre-incubation with Nacitrate, and 4-aminophenylboronic acid CQDs; (D) DCF-DA assay results depicting
oxidative stress inside the cell upon Rotenone introduction and the cell rescue upon preincubation with Na-Citrate, and 4-aminophenylboronic acid CQDs. Reproduced with
permission from Ref162.
We then exposed Na-citrate, and 4-aminophenylboronic acid CQDs to rotenone-challenged
cells (Figure 23A). A gradual increase in cell-death was observed as a function of increasing rotenone
concentration (data not shown). Based on the results, we chose rotenone concentrations at 5 µM for
insulting the cells as ~ 40% cell death was observed within 24 hours of addition. The experiment was
performed using the Hoechst 33342 and Propidium Iodide (PI) dyes95. Hoechst 33342 is a nonintercalating dye that binds to the minor groove of the DNA and emits blue fluorescence. Whereas PI
only enters dead cells (cells whose selective permeability has been lost) and emits red florescence upon
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binding to the DNA by intercalating between the base pairs. The experimental results showed that both
Na-citrate, and 4-aminophenylboronic acid CQDs were able to partially resolve, in a dose-dependent
manner, the cell-death arising from rotenone toxicity.
We next examined the mechanism of rotenone-induced cell-death and the impact of the CQDs
using apoptosis and necrosis assays using the Annexin V-FITC dyes (Fig 23B and C)95. When a cell is
destined to undergo apoptosis, the phospholipid phosphatidyl serine which is normally presently in the
inner leaflet of the cell membrane gets translocated to the outer leaflet of the cell membrane and marks
the cell for apoptosis. Annexin V is an anticoagulant which can selectively bind to phosphatidyl serine
in a calcium-dependent manner. This method is used by Annexin V-FITC to bind to the phosphatidyl
serine and emit green fluorescence. The SYTOX green dye binds to the cellular nucleic acids of the
necrotic cells, as it is impermeable to live and apoptotic cells, and gives intense green fluorescence.
After staining the cell population, the apoptotic cells emit green fluorescence, necrotic cells emit a
higher level of green fluorescence and live cells emit little or no fluorescence. Our experimental data
showed that the exposure of rotenone (5 µM) provoked both apoptotic and necrotic pathways in the
cell line. Pre-incubation of the cells with either Na-citrate, and 4-aminophenylboronic acid CQDs and
upon pre-incubation with Na-citrate, and 4-aminophenylboronic acid CQDs reduced the percentage of
cell death in either pathway. It is important to note that treatment of the cell with Na-citrate, and 4aminophenylboronic acid CQDs alone was no different from untreated controls.
Finally, we wanted to determine the reason for the cell death. For this, we used DCF-DA dye.
It is a fluorogenic dye that measures the amount of hydroxyl, peroxyl and other ROS inside the cell.
DCF-DA molecule diffuses inside the cell where it is deacetylated by the esterase enzyme into its nonfluorescent counterpart87, 111-113. This compound when comes in contact with the ROS is oxidized to
DCF which is highly fluorescent. Using this dye, we determined the impact of Na-citrate, and 4aminophenylboronic acid CQDs on rotenone-induced intracellular stress. Results from the DCF-DA
assay indicate that rotenone was creating stress inside the cells. Whereas, both Na-citrate, and 4aminophenylboronic acid CQDs were able to mitigate rotenone-induced oxidative stress inside the cell
(Fig 23D). Importantly, the presence of CQDs alone created stress levels similar to that observed in
untreated cells. Hence, we can conclude that CQDs that are efficient at scavenging free radicals and
preventing the sequelae of events arising from ROS stress are useful in targeting neurodegenerative
diseases such as PD.
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2.5. CQDs as a bioimaging agent
Hoechst 33342

CQDs

Merge

4-PBA CQD

Na-Cit CQD

UT

Bright Field

Figure 24: Bioimaging using Na-citrate (A), and 4-aminophenylboronic acid CQDs (B) after 6 hours
of incubation. The nucleus is stained using the Hoechst 33342 dye and the cytoplasm is
stained with CQDs. UT is untreated cells. Reproduced with permission from Ref162.
We tested whether CQDs could be imaged inside cells. The first panel (Fig 24) shows the
confocal images of the untreated and treated cells, the second panel shows the nucleus of cells stained
with DAPI. The third panel depicts CQDs inside the cell as evident from self-fluorescence. The last
panel shows the merged images indicating the localization of the CQD in the cell. The data for imaging
results for 4-aminophenylboronic acid CQDs mirrors those for Na-citrate CQDs. i.e., 4aminophenylboronic acid CQDs was also able to be imaged inside the cell where it was found to be
localized inside the cell. The fluorescence intensity from the Na-citrate, and 4-aminophenylboronic acid
CQDs is less compared to the DAPI but the nanoparticles show a stable luminescence in cells, unlike
the organic dyes that undergoes photobleaching with time. Also, compared to 4-aminophenylboronic
acid CQDs, Na-citrate CQDs displayed higher fluorescence.

Hence, our Na-citrate, and 4-

aminophenylboronic acid CQDs could be used to trace nanoparticle/drug entry into the cells and can
also be effectively used for the diagnosis and imaging applications168-172.
53

3. DISCUSSION
As aforementioned, chemically functionalized CQDs have been instrumental in tailoring, and
optimization of CQD function for specific applications144-159. Frequently, applications require CQDs to
be multi-functional. For example, within the biological ambit it would be desirable for CQDs
intervening in neurodegenerative disorders to be responsive to multiple outputs associated with the
progress of such disorders. The trajectory to PD, AD and other protein-misfolding-associated
pathologies is initiated by mitochondrial dysfunction leading to the i) soluble-to-toxic transformation
of amyloid proteins159 and ii) elevated levels of ROS173-176. Our study demonstrates that Na-citrate, and
4-aminophenylboronic acid CQDs are successful in scavenging free radicals and inhibiting fibril
formation.
There are at least three possible mechanisms by which to prevent fibril formation. These
includes inhibition of primary nucleation (i), secondary nucleation (ii), and elongation steps. The fibril
inhibition activity of Na-Citrate, phenylboronic acid, and 4-aminophenylboronic acid CQDs could be
attributed to the ability of CQDs to envelop the fibrils and block the self-seeding effect149, 159, 177-179. It
could also be due to the ability of CQDs to bind to the C-terminus of fibrils or protofibrils, which have
a comparatively lower degree of freedom and accessibility for the elongation process. CQDs could be
preventing seed growth via eliminating the templating domain (β-sheet) responsible for seeding and
seed propagation in amyloidogenesis (evident through our CD data). The CQDs could also be
interacting via hydrophobic and pi-pi stacking interaction with the monomeric species or intermediates,
and preventing fibrillation. The CQDs owing to their small size, high surface area, and charged surface,
can form electrostatic interactions and H-bonding with fibrils inducing disaggregation and destruction
of the already formed fibrils149,

159, 177-179

. The comparatively better fibril inhibition activity of

phenylboronic acid CQDs could be due to its highly oxygen rich surface compared to Na-Citrate, and
4-aminophenylboronic acid CQDs which bears amino functional groups on their surface in addition to
oxygen containing groups. CQDs with oxygen rich surfaces have been reported to dissolve amyloid
fibrils better116. Nevertheless, additional research is needed to discern the mechanism by which CQDs
are able to prevent and dissolve fibril formation.
The DCF-DA assays reports elevated ROS level in cells insulted with rotenone compared to
untreated cells and cells that were treated with CQDs alone. This elevated level of ROS can decouple
mitochondrial complex I along the oxidative phosphorylation pathway, which in turn can cause
mitochondrial membrane depolarization. This change in membrane polarization can then signal
cytochrome c release through the mitochondrial permeability transition pore (MPTP), and facilitate the
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influx of Ca2+ into mitochondria (caused by lipid peroxidation and reduced membrane fluidity). Cyt C
can then activate caspase 9 which in turn can activate caspase 3 which can then signal neuronal death
by apoptosis1, 87, 111-113, 138.
However, cells that were pre-incubated with our CQDs displayed reduced ROS level compared
to rotenone-insulted cells. The possible mechanisms for free radical scavenging using CNMs include
(i) hydrogen atom transfer (HAT), electron transfer (ET) and radical adduct formation. Na-Citrate, and
4-aminophenylboronic CQDs were able to acts as free radical scavenger by HAT (evident through
DPPH assay), ET (evident through FRAP assay) and adduct formation owing to their sp2 hybridized
carbon interior180, 181. The presence of functional groups like hydroxyl and amines on the surface and
edges of CQDs are responsible for their free radical scavenging abilities and neuroprotective
behavior180-182.
Previous work reveals that Graphene Quantum Dots, which differ from CQDs, interfere in
synuclein pathology157. Furthermore, multi-functional CQDs have found applications in antitumor
therapy, in imaging and gene delivery, and for antioxidant activity coupled with sensing141, 144, 146, 147,
152

. The hydrothermal synthesis of CQDs has also been previously described148, 149. What is novel in

this study, as the title suggests, is the ability of the CQDs to interfere in a multi-pronged manner in
neurodegenerative onset via the simultaneous targeting of two key features, viz elevated levels of
reactive oxygen species and the soluble-to-toxic transformations of amyloids, associated with
pathogenesis. This is important and novel because previous reports have revealed that protein
aggregation and oxidative stress interact and intensify each others’ effect ultimately resulting in
neuronal death1, 8, 138. Therefore, it is crucial to advance “one-pot” drugs with multifactorial points of
intervention. This is increasingly becoming important as disease are being recognized as not being
monogenic in nature but instead progressing via a plethora of molecular aberrations that are
sporadic/idiopathic.
4. CONCLUSION
Our findings indicate the Na-citrate, and 4-aminophenylboronic acid CQDs are each capable
of performing dependent biological functions. They are able to prevent the toxic-transformation of
amyloid proteins, restitute cellular homeostasis via scavenging of free radicals, and rescue cell lines
from apoptosis and necrosis induced by mitochondrial poisoning112,

113

. Furthermore, the intrinsic

fluorescence of CQDs facilitates the mapping of their distribution in cells, tissues and organs. Our data
show that Na-citrate, and 4-aminophenylboronic acid CQDs can be imaged in cells. The distribution is
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uniform and there is no aggregation visible. The in vitro data is a first step towards in vivo
bioimaging123,

168-172

. These dependent features highlight the versatility of CQDs. Not only can

individual CQDs be used for select functions but they can be applied to discrete scenarios. In future,
CQDs could be multi-functionalized where specific functional groups are introduced for specific
applications. Further tuning and refinement of CQD efficacies is possible through Structure-ActivityRelationship analyses173-175. Such a strategy would facilitate the development of highly optimized
designer CQDs that provide a one-pot approach to resolving problems not only in biomedicine but
across distinct and diverse domains. Importantly, since CQDs can be sourced from waste biomaterials
using biofriendly, green chemical techniques, it represents a versatile and sustainable avenue for
promoting biomedicine.
5.

MATERIALS AND METHOD

5.1. Materials
All reagents were commercially sourced as follows: Dimethyl sulfoxide (DMSO) (Fisher
Chemical, UK), Sodium citrate (Fisher Chemical, UK), Phenylboronic acid (Acros Organics, USA), 4Aminophenylboronic acid hydrochloride (Chem-Implex Int Inc.), Ethylene diamine (Fisher Chemical,
USA), Hoechst 33342 fluorescent stain (Invitrogen, USA), propidium iodide (PI) (Invitrogen, USA),
Annexin V- FITC apoptosis kit ( Abnova, USA), Carboxy-H2DCFDA (Invitrogen, USA), Quinine
Sulfate fluorescence (AnaSpec, USA), 1,1-diphenyl-2-picryl-hydrazyl (DPPH, Millipore-Sigma,
USA), potassium persulfate (Fisher Chemical, UK), Iron (III) chloride hexahydrate (Acros Organics,
USA), 2,4,6-Tripyridyl-S-triazine (Chem-Impex Int’l Inc.), lysozyme (MP Biomedicals LLC, France),
Thioflavin T and Rotenone (Sigma-Aldrich, USA), Fetal Bovine Serum (FBS) (Atlanta Biologicals,
USA), Dulbecco's modified Eagle's medium (DMEM) (Corning, USA), Rotenone (Sigma Aldrich,
USA), and a human neuroblastoma cell line SH-SY5Y (ATCC, USA). All reagents were of analytical
grade and were used without further purification.
5.2. Preparation of CQDs from sodium citrate, Phenylboronic acid, and 4Aminophenylboronic acid
CQD1: The nanoparticles were synthesized using established “bottom-up techniques” 159, 183. In
brief, sodium citrate (2.1g) was dissolved in 20 mL milli-Q water. Later, in a dropwise fashion,
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ethylenediamine was introduced (670 µL). The mixture was stirred for 10 minutes at 500 rpm on a
magnetic stirrer. The colorless solution was then transferred into a 100 mL Teflon-lined autoclave and
heated at 200 oC for 6 hours. Later, the resulting product was allowed to cool to room temperature. The
product was transferred into a dialysis bag of MWCO 6K and dialyzed against Milli Q water for 24
hours at 120 rpm at room temperature. This step was done to remove any unreacted reactants if present.
Particles were then lyophilized at -85 oC and 0.500 Atm and stored at 4oC for further analysis.
CQD 2 and 3: Phenylboronic and 4-aminophenylboronic acid (200 mg/20 mL) were dissolved
in Milli Q water183. The pH of the resulting solution was adjusted to 9 by using sodium hydroxide (1
M). The solutions were then transferred into a 100 mL Teflon-lined autoclave and heated at 160 oC for
8 hours. Later, the resulting product was allowed to cool down at room temperature. The products were
then transferred into a dialysis tubing of MWCO 6K and dialyzed against Milli Q water for 24 hours at
120 rpm at room temperature. This step was done to remove any unreacted reactants if present. Particles
were then lyophilized at -85 oC and 0.500 Atm and stored at 4oC for further analysis.
5.3. Characterization
The UV/VIS spectra of sodium citrate (CQD 1), phenylboronic acid (CQD 2), and 4Aminophenylboronic acid (CQD 3) CQDs were obtained using a Chemglass Life Sciences SpecMate
UV-Vis spectrophotometer in the 200 - 800 nm scan range. Whereas the morphology of the CQDs 1-3
was analyzed using TEM (H-7650, Hitachi High Technologies America, USA). Thermo Scientific
Nicolet iS5 spectrometer was used for obtaining the IR spectra of the as-synthesized CQDs 1-3 in a
KBr matrix (8). The scan range was from 500-4000 cm-1. The Raman spectra of the CQDs 1-3 were
obtained using a NT-MDT spectra II. The fluorescence spectra of the as-synthesized CQDs 1-3 were
obtained using a DM45 Olis spectrofluorimeter (On-line Instrument Systems, Inc.) equipped with a
water bath set to 24 oC.
5.4. QY%
Fluorescence Quantum yield (Q) of CQDs 1-3 was calculated using quinine sulfate (Q = 54%)
in 0.1 M sulfuric acid as a reference. The Q for CQDs was calculated using the following formula:
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Where, “a” refers to the measured integrated emission intensities of the sample (sam) and reference
(ref), “A” refers to the absorbance, and “n” is the refractive index of the solvent used. The Q calculated
for CQD 1 was 44.5%, CQD 2 was 16.8%, and CQD 3 was 20.3%.
5.5. Monomer to fibril transformation assays
Native lysozyme solution (2mg/mL) was prepared in potassium phosphate buffer (20mM, pH
6.3, 4 M GdHCl). Next, the lysozyme solution was introduced into nine glass vials (10 mL).
Subsequently, CQDs 1-3 were introduced at concentrations 1 mg/mL and 5 mg/ml into these vials and
labeled accordingly. lysozyme without CQDs was used as control. The vials were then put in an
incubator shaker (Multi-Therm, Benchmark) for 8 hours at 45 oC and 550 rpm. After 8 hours, the vials
were taken out from the incubator shaker. The solutions were then centrifuged at 12,000 rpm, and the
supernatant was discarded and replaced with water. This process was repeated four times. The obtained
pellet was then mixed with water in new vials, labeled accordingly, and analyzed using Fluorimeter
(ThT assay) and Circular Dichroism (observing protein's secondary structure)159, 184.
Fluorimeter: ThT solution was prepared in water (2 mg/mL). The excitation and emission
wavelengths in the fluorimeter were fixed at 450 nm and 480 nm, respectively. Later, in a cuvette, water
(1500 µL) and ThT (20 µM) were introduced. Subsequently, the solutions (500 µL) from vials were
added, and the measurement was recorded for each vial.
Circular Dichroism: The solutions from the vials (40 µL) were added to the cuvette
(fireflysci.com) and measurements was obtained using the Circular Dichroism (JASCO 1500). The
parameters were fixed at bandwidth = 1.00 nm, measurement range = 190-260 nm, data pitch = 0.1 nm,
scanning speed = 50 nm/min, and accumulation = 3 times.
5.6. In test-tube antioxidant assays
The antioxidant activity of the as-synthesized CQDs 1-3 was determined using the DPPH and
FRAP assay (31-33).
DPPH assay: Briefly, the stock solution (2 mM) was prepared in methanol. Different CQDs 1-3
concentrations (0 -100 µg/mL) were mixed with 1 mL of the DPPH solution in a quartz cuvette. A color
change of the solution from violet to yellow in a cuvette on mixing was observed, indicating the free
DPPH radicals' neutralization107-110. Later, the UV-Vis scan in the range of 300-800 nm was recorded,
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and changes in the absorbance of the DPPH methanolic solution (with and without CQDs) at 517 nm
were observed and plotted.
FRAP (Ferric Reducing Antioxidant Power) assay: Briefly, 3.1 g of sodium acetate trihydrate was
dissolved in 800 mL of water. To this solution, 16 mL of glacial acetic acid was added, and the pH of
the solution was adjusted to 3.6 using the 1N NaOH and 1N HCl. The final volume of the solution was
brought to 1 L using water. The solution was clear and colorless and was stored at room temperature.
10 mmol/L TPTZ solution was prepared in HCl, and the reagent was stored at room temperature. 20
mmol/L of ferric chloride solution was prepared in water and stored at 40C. Finally, a working FRAP
solution was prepared by mixing 10 mL acetate buffer with 1 mL TPTZ solution and 1 mL of ferric
chloride solution. The color of the working FRAP solution was pale yellow-orangish107-110. Different
CQDs 1-3 concentrations (0-100 µg/mL) were mixed with 1 ml of the DPPH solution in a quartz
cuvette. Later, the UV-Vis scan in the range of 300-800 nm was recorded, and changes in the absorbance
of the FRAP solution (with and without CQD) at 593 nm were observed and plotted.
5.7. Cell culture
The SH-SY5Y cells were grown in T-75 in DMEM with 10% FBS (v/v) and 1% (v/v) penicillinstreptomycin95, 137. The cells were incubated at 37 °C in an incubator with an atmosphere of 5% CO2.
The media was changed two to three times per week. Further, Trypsin-EDTA was used to detach cells
from the T-75 flask to seed/plate 96 and 24 well plates for various cell studies/experiments.
Cytotoxicity studies: To determine the percent of live and dead cells, Hoechst 33342 and PI
dyes were used. Briefly, a 96 well plate with 10,000 cells/well was prepared and incubated for 24 hours
to attach cells onto the plate's surface95, 137. The untreated cells were taken as a negative control, whereas
cells treated with hydrogen peroxide served as the experiment's positive control. The cells were then
pre-treated with different CQDs 1 and 3 concentrations (0 -120 µg/mL) to select benign and effective
concentrations. Later, four different concentrations (60, 80, 100, 120 µg/mL) were selected to move
forward with the experiment. The cells were first pre-incubated with the CQDs 1 and 3 (60- 120
µg/mL), and after 6 hours, rotenone at concentration 5 µM was introduced followed by 24 hours of
incubation at 37 oC. After 24 hours, 20 µL of PI/Hoechst 33342 mixture was added to each well,
followed by incubation in the dark at 37oC for one hour. Finally, the well plate was taken out of the
incubator, and the images were captured using the Bioimager system (BD Biosciences Rockville, USA)
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95, 137

. The obtained data was then read using the BD AttoVision v1.6.2 software to determine the

percentage of live and dead cells/well.
Apoptosis/Necrosis assay: Briefly, for this assay, the cells were plated at a density of 100,000
cells/well in a 24-well plate. This well plate was then incubated for 48 hours to allow cellular
attachment. The cells were then pre-treated with the select 80 µg/mL of the as-synthesized CQDs 1 and
3 six hours before introducing rotenone (5 µM). The well-plate was then incubated for additional 24
hours. After 24 hours, the cells were recovered from each well, washed with 1X PBS, and stained using
the Annexin V- FITC apoptosis kit from Abnova following the manufacturer's protocol95, 137. The plate
was then finally analyzed using a Cytomics FC 500 Beckman Coulter Flow cytometer with 10,000
events captured for each sample and analyzed using the Beckman Coulter CXP software.
DCF-DA assay: To measure the amount of reactive oxygen species generated upon introduction
of rotenone and free radical scavenging potential of our CQDs 1 and 3, we first cultured the cells in a
24 well plate at a density of 100,000 cells/well. The plate was incubated for 48 hours to allow cellular
attachment to take place onto the well plate's surface. Subsequently, the cells were pre-treated with
select 80 µg/mL of as-synthesized CQDs 1 and 3 six hours before introducing rotenone (5 µM) followed
by additional incubation of the cells for 18 hours. After 18 hours, the cells were detached using the
trypsin and harvested in flow cytometry tubes. The tubes were then centrifuged at 1,200 rpm for 5
minutes, followed by decanting the supernatant without disturbing the pellet. A master mix consisting
of PBS and DCFD-DA reagent was prepared95, 137. This master mix was then added to each flow
cytometry tube, and the tubes were then vortexed at low speed to make sure that the pellet has dissolved.
The tubes were then incubated for 1 hour at 37oC in the dark. The tubes were centrifuged again (1,200
rpm, 5 minutes) to remove any additional dye if present. The supernatant was then decanted, and prewarmed 1X PBS (500 µL) was added to each tube. The tubes were then incubated at 37oC for additional
20-30 minutes. The cells were then finally analyzed using a Cytomics FC 500 Beckman Coulter Flow
cytometer with 10,000 events captured for each sample and analyzed using the Beckman Coulter CXP
software.
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Chapter 4: Gelatin-derived Carbon Quantum Dots Mitigate Herbicide-Induced Neurotoxic
Effects In vitro and In vivo
ABSTRACT
The herbicide and viologen, N, N′-dimethyl-4,4′-bipyridinium dichloride (Paraquat) is known to be
toxic to neuronal cells by a multifactorial process involving an elevation in the levels of reactive oxygen
species (ROS), the triggering of amyloid-protein aggregation and their accumulation, collectively
leading to neuronal dyshomeostasis. We demonstrate that green-chemistry-synthesized sustainable
gelatin-derived carbon quantum dots (CQDs) mitigate paraquat-induced neurotoxic outcomes and
resultant compromise in organismal mortality. Gelatin-derived CQDs were found to possess antioxidant
properties and ameliorated ROS elevation in paraquat-insulted neuroblastoma-derived SHSY-5Y cells,
protecting them from herbicide-induced cell death. These CQDs also increased lifespan in paraquatcompromised Caenorhabditis elegans and herbicide-mediated dopamine neuron ablation. Collectively,
the data underscore the ability of this sustainably synthesized, environmentally friendly biocompatible
nanomaterial to protect cell lines and organisms against neurotoxic outcomes. The study findings
strategically position this relatively novel nanoscopic carbon quantum framework for further testing in
vertebrate trials of neurotoxic insult.
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1. INTRODUCTION
Pesticides (including insecticides, weedicides, and herbicides) have been in use for many years
and serve invaluable functions in protecting against agricultural wastage, securing arable soil, and
mitigating vector-borne disease losses185. However, these xeno-chemicals also harm non-target
organisms, including humans. Chronic exposure to pesticides, including fungicides, piscicides, and
herbicides, correlates with neurotoxic outcomes. Studies have associated pesticide exposure with
sporadic Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD) disease, amyotrophic lateral sclerosis
(ALS), multiple sclerosis (MS), and even autism186-192. The molecular underpinnings by which these
xenotoxicants elicit neuronal injury and neuronal demise involve the production of reactive oxygen
species, which decouples complex I along the oxidative phosphorylation pathway in mitochondria188.
The herbicide, Paraquat and piscicide, rotenone, inhibit complex I, impair proteasomal function, and
drive the degeneration of neurons193, 194. In vitro studies indicate that Paraquat induces conformational
changes in α-Synuclein (α-Syn) and stimulates its aggregation194,

195

. They modulate intracellular

calcium levels and provoke the phosphorylation of α-Syn and its aggregation195. In addition, it inhibits
autophagy which exacerbates the accumulation of aggregated α-Syn196.
The soluble-to-toxic conversion of amyloid proteins such as α-Syn, amyloid-beta (Aβ), mutant
Huntingtin (mHTT), for example, are associated with the onset and progression of their
(aforementioned) associated neurodegenerative disorders159. As previously discussed, exposure to
pesticides results in mitochondrial disruption, loss of cellular homeostasis, and the accumulation of
toxic forms of otherwise soluble amyloid proteins. Therefore, mechanisms to restore neuronal
proteostasis under pesticide exposure remain an unmet need.
CQDs are a unique class of carbon nanomaterials (CNMs) that have shown promise in a variety
of biomedical applications139-143. These are nanosized CNMs that have attracted widespread attention
since their first discovery as environmentally friendly alternatives to toxic quantum dots (QDs), which
suffer from health and environmental-related concerns. They are easily synthesized from carboncontaining precursors such as fruit peel, leaves, wood pulp, and amino acids, using facile and
environmentally friendly hydrothermal synthesis methods. Coupled with the fact that they are sourced
from biowaste, CQD generation qualifies as “green chemistry” (green chemistry is the design of
chemical products and processes that reduce or eliminate the generation of hazardous substances)141.
CQDs owing to their wonderful properties such as nontoxicity, high quantum yield with a tunable
bandgap, cost-effectiveness, high specific surface area, biocompatibility, hydrophilicity, excellent water
dispersibility, ease of surface functionalization, chemical inertness, and resistance to photobleaching,
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have found applications in theranostic, bioimaging, sensing, biomedicine, electrocatalysis and
optronic139-143. The rich sp2 hybridized structures of CQDs, along with their tunable surfacecharacterization properties, have provided them with antioxidant properties and the ability to cross the
blood-brain barrier142. Previous work has also revealed that they are able to intervene in the soluble-totoxic transformation of amyloid proteins such as α-Syn and hen-egg white lysozyme (HEWL)159.
Here we have explored, in vitro and in vivo, whether gelatin-derived CQDs can rescue cellular
and organismal aberrations associated with paraquat-induced toxicity. Our results suggest that the
CQDs are neuroprotective and successfully intervene in mitigating paraquat-driven cellular and
organismal deficits.
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2. RESULTS
2.1. Characterization of Gelatin-derived CQDs
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Figure 25: (A) Schematic representation of the CQD synthesis method; (B) TEM image and (C)
Histogram particle size distribution obtained using TEM.
Gelatin-derived CQDs were characterized to establish their morphological and physicochemical
properties (Figure 25). Figure 1 shows a representative microscopy (TEM) image of the gelatin-derived
CQDs, which appear as discs of various sizes. The size distribution of the CQDs reveals a relatively
uniform distribution of particles with an average size 25 nm. A few particles were found to be larger,
with diameters approaching 50 nm.
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Figure 26: Characterization of Gelatin-derived CQDs: (A) absorption spectrum with the inset
showing fluorescent image of CQD when excited using the UV lamp, (B) Excitationdependent CQD emission spectra, (C) FTIR spectrum showing the presence of
functional groups, and (D) XRD diffractogram.
The absorption spectrum (Figure 26A) is typical of what is typically observed for CQD optical
absorption behavior159, 197. The gelatin-derived CQDs demonstrated absorption at wavelengths in the
range of 280-350 nm, suggesting the presence of sp2-hybridized architectures and, therefore, the ability
to scavenge free radicals159, 197. The presence of conjugated domains is also validated via the bluish
fluorescence observed upon illumination of the sample with UV light (Figure 26A inset).
To further characterize the fluorescence properties of gelatin-derived CQDs, we assessed the
excitation-dependent emission spectra of the sample. As shown in Figure 26B, the emission wavelength
is red-shifted as a function of increasing excitation wavelength. Specifically, as the excitation
wavelength is increased from 300 to 420 nm, the emission red-shifts to 490 nm (from 440 nm). The
excitation-dependent emission fluorescence is typical for CQDs, which possess multiple chromic
centers which get excited at different wavelengths depending upon their chemical constitution159, 197.
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In Figure 26C, the IR spectrum shows various functional groups that are present on the CQDs
159, 197

. The spectrum reveals the presence of oxygen-containing functional groups such as C=O (1700

cm-1) and C-O (1100 & 870 cm-1). Furthermore, amino-containing groups are identified by a broad
absorption band around 3200 cm-1 and a sharp peak at 1510 cm-1 in the spectrum. In addition, sulfurcontaining groups are evident through S-H stretching vibrations at 2620 cm-1 and S-C stretching
vibrations at 680 cm-1. Alkyl and aryl groups are inferred by C-H vibrations at 2950 cm-1, C=C
vibrations at 1420 cm-1, and C-C vibrations at 1330 cm-1.
In Figure 26D, the XRD data show a weak broad reflection centered around 220. This theta
value is indicative of the interlayer spacing of 0.41 nm with lattice parameters (002). This increased
spacing compared to d=0.34 nm of graphite is attributed to the presence of functional groups159, 197.
2.2. Determination of antioxidant potential of Gel-derived CQDs using DPPH assay
Free radicals are atoms or molecules that bear unpaired electrons. These unstable structures try
to electron-pair with macromolecules such as protein, DNA/RNA, and lipids inside the cell, initiating
radical-induced oxidative damage. Therefore, this section of the article tests the in-test tube antioxidant
potential of CQDs before transitioning to the cell line using the standard DPPH assay8, 107-110.
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Figure 27: Antioxidant capability of gelatin-derived CQDs: Free radical scavenging ability of CQDs
determined using the DPPH assay.
Figure 27 shows results from the ROS scavenging assay using DPPH8, 107-110. We examined the
ability of gelatin-derived CQDs to scavenge free radicals in the solution. This colorimetric assay is
based on the ability of an antioxidant (CQD in our case) to neutralize the diphenylpicryl hyradzyl
bearing an odd number of electrons on the nitrogen atom to diphenylpicryl hydrazine. This
neutralization could also be visualized by the change in color of the solution in cuvette from violet to
yellow upon the addition of an antioxidant. Compared to DPPH alone (Figure 27), the introduction of
the CQDs demonstrated a dose-dependent reduction in the UV absorption maximum at 520 nm.
Specifically, a 5-fold increase in gelatin-derived CQD concentration from 0 to 100 μg/mL resulted in
the complete elimination of absorption. These data imply that gelatin-derived CQDs are potent ROS
scavengers in the low micromolar range.
2.3.Cell-based assays: Cytotoxicity, Cell rescue, and DCF-DA assays
The Reactive oxygen species initiate pathophysiological conditions such as neurodegeneration
by altering the cellular response, which results in a diseased state. To maintain the level of ROS under
control, the living system has evolved to have enzymes (superoxide dismutase, glutathione peroxidase,
catalase) as part of a self-defense mechanism138, 198. These enzymes can efficiently neutralize ROS
resulting in enhanced cellular defense against oxidative stress. However, the problem arises when the
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balance between ROS generation and its removal is disturbed, resulting in the elevation of ROS level
inside the cell. Such an abrupt increase in ROS level occurs either due to genetic mutations in the
endogenous enzymes or overexposure to environmental toxicants such as Paraquat. These oxidizing
agents can cause oxidative damage to biological macromolecules such as DNA/RNA, proteins,
carbohydrates, and lipids inducing oxidative stress inside the cell and hence the onset of disease. These
ROS can also target mitochondria, the powerhouse of the cell, resulting in its dysfunction. ROS can
also induce Golgi apparatus fragmentation. Such homeostasis-disrupting events, redox imbalance, and
triggering apoptosis/necrosis pathways within the cell result in the onset of neurodegenerative
phenotype inside the cell line138, 198. Therefore, this section of the article is dedicated to investigating
the effect of Paraquat on neuroblastoma cells and if pre-incubation with Gel-CQDs could rescue cells
from paraquat-induced cell insult.
Figure 28A shows results from an assay used to determine the cytotoxicity of gelatin-derived
CQDs tested on a SHSY-5Y cell line74, 87, 159. The experiment was performed using the Hoechst 33342
and Propidium Iodide dyes. Hoechst 33342 is a cell-permeable, popular fluorescent dye for labeling
DNA. It emits a blue/cyan fluorescent light (~460 nm) when excited at 350 nm. PI is also a dsDNA
binding dye but can only permeate those cells that have lost their cell membrane (i.e., cells undergoing
apoptosis or necrosis) and hence used to detect dead cells. It emits red fluorescent light (~630 nm) when
excited at 490 nm. The introduction of CQDs (0-100 μg/mL) to the cell line did not impact cell death
over the levels observed in untreated controls. The level of cell death observed was also a fraction of
the positive control (H2O2). These results provide a concentration window for the gelatin-derived CQD
used in the following assays.
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Figure 28: Cytotoxicity, and Cell rescue assay using gelatin-derived CQDs: (A) Cytotoxicity of
CQDs at different concentrations. Rescue of cells from paraquat-induced cell death by
CQDs (B) where sample # 1 is Untreated, # 2 is @ CQDs at 50µg/mL, # 3 is CQDs @
100µg/mL, # 4 is CQDs @ 200µg/mL, # 5 is cell rescue from 1mM paraquat insult by
the CQDs (100µg/mL), # 6 is paraquat insult at a concentration 1 mM, # 7 is cell rescue
from a 10 mM paraquat insult by the CQDs (100µg/mL), # 8 is paraquat insult at a
concentration 10 mM, # 9 is hydrogen peroxide (positive control). P value less than 0.05
is considered statistically significant. Confocal images of cells showing (C) (i) untreated
cells, (ii) CQD treated cells (100µg/mL), (iii) Paraquat insulted cells (10 mM), and (iv)
rescue of cells from Paraquat by the CQDs.

Figure 28B is a composite graph of both paraquat-induced toxicity to SHSY-5Y cells and the
ability of gelatin-derived CQDs to intervene in paraquat-induced cell death. Bar # 6 depicts paraquatassociated cell death at a xenotoxic concentration of 1mM. However, when the cell-line was previously
incubated with gelatin-derived CQDs (100µg/mL), there was a statistically significant attenuation seen
in cell death. The results were also found to be statistically significant at a paraquat-exposure level of
10 mM) by the CQDs (100µg/mL), suggesting the prophylactic efficiency of the gelati-derived
nanomaterial in maintaining critical cellular functions under neurotoxic conditions. Figure 28C shows
the confocal microscopy imaging data where cells treated with Paraquat alone (iii) displayed stressed
circular morphology. Whereas cells that were pre-incubated with gelatin-derived CQDs (iv) and then
the Paraquat was introduced showed morphology similar to CQD treated cells (ii) and the untreated
control (i). Figure 29 shows the cytoskeleton staining of the cell using alpha-tubulin-Alexa 488 and
Phalloidin-Alexa 568. The untreated and cqds alone treated cells displayed an extended, well-organized
structure where microtubules and microfilaments were observed through the cell bodies and along the
periphery of the neurons. These cytoskeletons help in providing structural integrity to the cells. Whereas
the cells treated with paraquat displayed stressed and spherical morphology denoting cell shrinkage
compared to untreated cells. Whereas cells pretreated with cqds and then insulted with paraquat
displayed unaltered microtubule and microfilament organization. These results indicate that paraquat
caused an alteration in the microtubulin and microfilament network, as evidenced by the appearance of
the contracted and stippled pattern in the cells confirming its cytotoxicity.
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Figure 29: Cytoskeleton analysis using confocal immunofluorescent microscopy.

We examined whether gelatin-derived CQDs can mitigate paraquat-dependent ROS generation
within cells using the H2DCFA dye. Figure 30A shows the schematic representation of the mechanism
of dye action and fluorescence. The data in Figure 30B show ROS levels upon paraquat insult to the
SHSY-5Y cell line. Paraquat exposure at 1- or 10-mM results in a significant increase in cell death
compared to untreated controls. While the gelatin-derived CQDs were found not to elevate ROS at
100µg/mL, they were successful in significantly mitigating the aforementioned paraquat-related
intracellular ROS elevation at both concentrations of the insult tested (sample 3 vs. 4 and samples 5 vs.
6). Images in 30C are representative raw data from the DCF-DA assay.

71

B

A

C

(ii)

(i)

(iii)

(iv)

Figure 30: Effect of gelatin-derived CQDs on ROS scavenging capability: (A) Schematic
representation of the conversion of non-fluorescent dye to fluorescent counterpart in the
presence of ROS inside the cell. (B) sample # 1 is untreated cells, # 2 is CQDs
(@100µg/mL), # 3 is cell rescue from a 1mM paraquat insult by the CQDs
(@100µg/mL), # 4 is paraquat insult at a concentration of 1 mM, # 5 is cell rescue from
10 mM paraquat insult by the CQDs (100µg/mL), # 6 is paraquat insult at a
concentration of 10 mM. (C) shows (i) cell rescue from 1mM paraquat insultby the
CQDs (100µg/mL), (ii) paraquat insult at a concentration of 1 mM, (iii) cell rescue from
10mM paraquat insult by the CQDs (100µg/mL), (iv) paraquat insult at a concentration
of 10 mM.
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2.4. In vivo assays: Cytotoxicity and nematode rescue from paraquat insult using Gel CQDs
Next, we examined the impact of gelatin-derived CQDs on paraquat-associated C. elegans
mortality. As observed in Figure 31A, the introduction of 4 mM Paraquat to the agar medium results in
a compromise in nematode survival ~72 hours post-incubation of the xenotoxicant. This was further
confirmed by examining the percent survival as a function of paraquat dose (31B), wherein a reduction
in paraquat concentration elicited diminished levels of worm survival as anticipated. By contrast, the
introduction of gelatin-derived CQDs (0-2.0 mg had a relatively negligible impact on their survival
compared to 4 mM paraquat (31A). To determine whether gelatin-derived CQDs could protect the
nematode against paraquat-induced compromise in nematode survival, we preincubated gelatin-derived
CQDs (0.25- 2.0 mg) in the agar medium prior to a 2 mM paraquat challenge. CQD-dose-dependent
mitigation in paraquat-induced compromised mortality is observed (31C).
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Figure 31: Cytotoxicity Profile of a Range of Gelatin-derived CQD Concentrations on Paraquat
Poisoned BZ55 C. elegans. (A) Tg C. elegans (BZ555 C. elegans) treated with paraquat
at different concentrations. (B) Nematodes treated with Gelatin CQDs (Gel) at
concentration of 0.25 mg - 2mg. (C) Prophylactic activity of Gel CQDs on nematode
insulted with 2mM paraquat. Present data represent the % survival of (approximately 20
per group); dataset is unique to each experiment. Quantitative data representing mean
lifespan.
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To obtain further insight into the role played by gelatin-derived CQDs in mitigating
physiological damage induced by paraquat toxicity, we assayed the paraquat-dependent loss of
dopaminergic neurons C. elegans. Figure 32 (i-iii) shows the impact of paraquat and gelatin-derived
CQDs on (GFP-labelled) dopaminergic neurons in the nematode. Compared to the untreated control
and the medium, the exposure of 2 mM paraquat resulted in the ablation of ADE neurons. By contrast,
there was no statistically significant impact of gelatin-derived CQDs on either neuronal sub-type.
Importantly, when C. elegans were previously incubated with 0.5- 2 mg gelatin-derived CQDs (Figure
32 iii), a statistically significant level of protection from neuronal ablation was observed. The quantified
data are tabulated using the previously described formula.
Figure 32 (iv) shows representative microscopy images of the aforementioned results.
% of neurodegeneration=𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑜𝑟𝑚𝑠 𝑤𝑖𝑡ℎ 𝑑𝑒𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒𝑑 𝑛𝑒𝑢𝑟𝑜𝑛𝑠 / 𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
𝑜𝑓 𝑤𝑜𝑟𝑚𝑠 𝑋 100
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Figure 32: Fluorescence intensities of GFP-tagged DA neurons in normal BZ555 C. elegans. (i)
Representative images of the effects of CQDs on restoration of paraquat induced DA
neuron-degeneration in C. elegans as indicated by the GFP expression in DA neurons.
(A. Control, B.K-Medium, C. CQDs D. CQDs + paraquat E. 2 mM paraquat, and H2O2
(100µM). (ii) Control experiments to establish the toxicity profiles of paraquat and
gelatin-derived CQDs (iii) 2mM paraquat-challenged (PQ) worms were pre-treated with
gelatin-derived CQDS (Gel). (iv) The table shows the quantitative loss of neurons from
(i) and (ii). The data are presented as mean ± SD (30 animals per group). Asterisk (*)
indicates significant difference between control and paraquat-treated groups at P value <
0.05.

3. DISCUSSION
While gene defects play a role in the pathogenesis of neurodegenerative disorders, they
represent only 5-10 % of the observed cases180. Environmental and idiopathic incidences are implicated
in the rest of the observed cases. As previously discussed, the use of environmental pesticides, including
herbicides, fungicides, and weedicides, provokes neurotoxic outcomes in vertebrates, including
humans186-192. Therefore, the laboratory use of agents such as rotenone and Paraquat to accelerate
neurotoxicity and onset neuropathological outcomes is not only academically relevant but also of
clinical importance. As a corollary, mechanisms to restore altered neurocellular functions and aberrant
organismal behavior under xenotoxic stress remains a critical and unmet need in the neurodegenerative
arena.
Gelatin-derived CQDs are easily synthesized through waste biomaterial. These two aspects
categorize the process as being “green.” They display a conjugated structure that enables essential
biological properties. The fluorescent nature of the CQDs is a desirable feature for tracking the
biomaterial in vivo. The utility of the sp2-hybridized architectures present in the CQDs is validated by
results demonstrating that gelatin-derived CQDs scavenge free radicals (are antioxidant) in model
scenarios and can scavenge reactive oxygen species intracellularly. As a result, the nanomaterial was
able to protect the neuroblastoma-derived SHSY-5Y cell line from paraquat-induced ROS damage. The
possible mechanisms by which CQDs were able to serve as an antioxidant are (i) Hydrogen atom
transfer (HAT), Electron transfer (ET), and adduct formation180, 182, 199.
We also addressed whether the CQDs could protect nematodes from neurotoxicant-induced
mortality. C. elegans models recapitulate key features of PD, which include progressive
neurodegeneration, impairment of dopamine-dependent behavior and locomotor function, and
reduction in dopamine levels200-202. In a C. elegans model of paraquat-toxicity, our results revealed that
gelatin-derived CQDs could mitigate nematode mortality levels observed when exposed to paraquat77

alone. Importantly, gelatin-derived CQDs protected the nematode from dopamine-neuron ablation that
onset upon exposure to the herbicide. Since dopamine neurons regulate locomotor functions, the
preservation of these neurons under neurotoxic duress is a vital facet of these carbon materials.
4. CONCLUSION
Green chemistry synthesized, biocompatible gelatin-derived CQDs represent an important and
viable candidate in the campaign against environmental xenotoxicant-driven neurodegenerative onset.
Even though our focus was restricted to outputs specific to Parkinson’s Disease (PD) phenotypes and
onset, the increase in oxidative stress, free radical-induced loss of cellular homeostasis, protein
misfolding, neuronal injury, demise, and neurodegenerative onset are events that are common to other
neurodegenerative disorders such AD, HD, and ALS. We have previously demonstrated that CQDs can
intervene in amyloidogenic trajectories by intervening in the soluble-to-toxic transformation of
amyloid-forming proteins. Those results, coupled with these findings, position CQDs as important
candidates for preclinical trials.
5. MATERIALS AND METHODS
5.1. Materials
All reagents were commercially obtained (except for the CQDs which were synthesized), including 1,1diphenyl-2-picryl-hydrazyl (DPPH) (Millipore-Sigma USA), Penicillin/Streptomycin (15-140-122 Gibco),
Hoechst 33342 fluorescent stain (Invitrogen, Carlsbad, CA, USA), propidium iodide (PI) (Invitrogen, Eugene,
OR, USA), Gelatin (Sigma-Aldrich, USA), Fetal Bovine Serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA),
Carboxy-H2DCFDA (Invitrogen, USA), Methyl viologen dichloride hydrate (Paraquat, Sigma-Aldrich), SHSY5Y (ATCC, Manassas, VA, USA), Guanidine Hydrochloride (Fisher Scientific, USA), Potassium Phosphate
Dibasic and Monobasic (Fisher Scientific, USA), Ammonium Bicarbonate (Fisher Scientific, USA), TrypsinEDTA 0.25% (Life Technologies). The reagents were of analytical grade and were used without further
purification.

5.2. Gelatin-derived Carbon Quantum Dots Synthesis:
CQDs were synthesized using hydrothermal synthesis as previously described197. Briefly, 0.8g
of gelatin was mixed with 40 mL MilliQ water and agitated for an hour at 40 oC. This mixture was then
transferred to a Teflon-lined autoclave and heated at 200 oC for 4 hours. After cooling the mixture to
room temperature, the solution was centrifuged at 5000 rpm for 30 minutes, transferred to a dialysis
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bag (MWCO 6 KDa), and dialyzed against MilliQ water for 24 hours. The resulting solution was
collected, lyophilized, and stored until further use.
5.3. Characterization
The UV/VIS spectra of gelatin-derived CQDs were obtained (200 - 800 nm) using a Chemglass
Life Sciences SpecMate UV-Vis spectrophotometer. The morphology and size distribution of the CQDs
was determined by TEM (H-7650, Hitachi High Technologies America, USA). The IR spectra of the
CQDs were obtained using a Thermo Scientific Nicolet iS5 spectrometer. GEL CQDs' excitationdependent emission fluorescence spectra were obtained using a DM45 Olis spectrofluorimeter (On-line
Instrument Systems, Inc.)
5.4. Radical Scavenging Activity by DPPH Method:
Briefly, a stock DPPH solution (2 mM) was prepared in methanol. Gelatin-derived CQDs (0 100 µg/mL) were mixed with the DPPH solution as previously described107. Upon addition, a color
change from violet to yellow of the solution was observed, which is indicative of free DPPH radicals'
neutralization. For quantification, a UV-Vis scan in the range of 300-800 nm was recorded for each
concentration, and changes in the absorbance (with and without CQDs) at 517 nm were observed and
plotted as a function of CQD concentration.

5.5. Cell culture
Human neuroblastoma cells (SH-SY5Y) (ATCC, Manassas, VA) were grown in a culture
medium (DMEM/F12) supplemented with 10% fetal bovine serum (FBS). Prophylactically, 1% of
penicillin/ streptomycin was added to the medium. Cells were maintained by incubation at 37°C with
5% carbon dioxide. All cell work was performed at the Border Biomedical Research Center (BBRC)The University of Texas at El Paso.

5.6. Cell-based assays
Cytotoxicity profile of gelatin-derived CQDs: Cell viability was evaluated using Hoechst 33342
and PI dyes. Briefly, in a 96 well plate, ~10,000 cells/well were added, and the plate was incubated for
24 hours to allow attachment of cells onto the plate's surface74, 87. Once the plate was ready, the
experiment was performed by considering untreated cells as a negative control, and the cells treated
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with hydrogen peroxide served as the positive control. Meanwhile, the other wells were treated with
varying CQD concentrations (0 -100 µg/mL) to determine cytotoxicity. Later, a single CQD
concentration (100 µg/mL) was selected to proceed with succeeding experiments.
Cell rescue assay: To determine whether gelatin-derived CQDs could rescue cells from
oxidative stress and cytotoxicity, the cells were first pre-incubated with the CQDs (100 µg/mL) for 6
hours followed by either 1mM or 10 mM paraquat introduction. The cells were incubated for 24 hours
at 37 oC. After 24 hours, 20 µL of PI/Hoechst 33342 mixture was added to each well, followed by
incubation in the dark at 37oC for one hour. Finally, the images were captured using the Bioimager
system (BD Biosciences Rockville, USA). The results were quantified using a BD AttoVision v1.6.2
software to determine the percentage of live and dead cells/well. The plate images were also obtained
using a LSM700 confocal microscope to observe the morphology of the cells before and after the
introduction of the CQDs and Paraquat74, 87.
Confocal immunostaining assay: Cells were seeded at a density of 5000 cells/well in 100 µL of
media in a 96-well plate. The well plate was incubated overnight to allow cells to adhere. After 24
hours, the cells were treated with cqds (well 1), cqds followed by paraquat after 6 hours (well 2), and
paraquat alone (well 3). The untreated cells were used as control. At the end of the incubation time and
without removing the media, formaldehyde was added such that its final concentration in the well was
4%. The plate was incubated for ~20 minutes at room temperature. Later, paraformaldehyde was
removed, and 200µL of 0.1% tween 20 was added in PBS and cells were given three washes at an
interval of 10 minutes. Later, the cells were incubated with 5% BSA in TBS-T and left for overnight.
The next day cells were stained with 50µL of 0.1% tween 20 PBS solution containing 5µg/mL of DAPI,
0.156µM of Alexa Fluor 568-conjugated phalloidin (Invitrogen), and 0.5µg/mL of Alexa Fluor 488conjugated anti-alpha-tubulin monoclonal antibody (clone DM1A; Thermo Fisher Scientific) and left
for incubation for 1 hour at room temperature. The cells were later washed using the permeabilization
solution as previously described. Finally, the images were captured using the LSM-700 confocal
microscope (Zeiss) on three fluorescent channels (Alexa-488, alexa-586, and DAPI).
DCF-DA assay: This assay is used to identify and quantify the presence of intracellular ROS
upon introduction of an initiating source (such as Paraquat)

74, 87

. The experiment involved culturing

cells in a 24-well plate at a density of ~100,000 cells/well. The plate was then incubated for 24 hours
to allow cellular attachment. Once the plate was ready, experiments were performed by considering
untreated cells as a negative control, and the cells treated with hydrogen peroxide served as the positive
control. The cells in other wells were first pretreated with 100 µg/mL of the gelatin-derived CQDs six
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hours before introducing either 1 mM or 10 mM paraquat. The well-plate was then incubated at 37oC
for 18 hours. Later, the cells were detached using trypsin and harvested in flow cytometry tubes. The
tubes were centrifuged at 1,200 rpm for 5 minutes, followed by decanting the supernatant (without
disturbing the pellet). A master mix consisting of PBS and DCFD-DA reagent was prepared. This
master mix was then added to each flow cytometry tube, and the tubes were then vortexed at low speed
to ensure that the pellet dissolved. The tubes were incubated for ~1 hour at 37oC in the dark. The tubes
were centrifuged again (1,200 rpm, 5 minutes) to remove any additional dye. The supernatant was again
decanted and replaced with pre-warmed 1X PBS (500 µL) in each tube. The tubes were incubated at
37oC in the dark for additional 20-30 minutes. The cells were finally analyzed using a Cytomics FC
500 Beckman Coulter Flow cytometer with 10,000 events captured for each sample and analyzed using
the Beckman Coulter CXP software.
5.7. Culture and Maintenance of C. Elegans
The C. elegans strain used was the BZ555 variant (Pdat-1:GFP in the dopaminergic neurons)
purchased from the Caenorhabditis Genetics Center at the University of Minnesota USA. BZ555
possesses eight neurons classified as two anterior deirid (ADE), two dorsal cephalic (CEP) that are
postsynaptic to the ADE, two ventral CEPs that are not postsynaptic to the ADEs, and two posterior
deirid neurons (PDE). Synchronized worms were obtained by bleaching a mixed population containing
plate, including gravid adult nematodes. Eggs were harvested by introducing 1M NaOH, 6% RICCA
sodium hypochlorite solution into 15 mL tubes followed by multiple washes with M9 buffer (2 g/l
KH2PO4, 5 g/l NaCl, 6 g/l Na2HPO4, 1 mM MgSO4). The nematodes were incubated at 20°C in
nematode growth medium (NGM) plates seeded with Escherichia coli (E. coli) strain OP50, as
described in Wormbook.org.
5.8. Paraquat and gelatin-derived CQD Treatment Protocols
Paraquat (Sigma-Aldrich) was dissolved in distilled and sterilized water to produce a 1 M stock
solution. The stock solution was then used to prepare paraquat plates at different concentrations ranging
from 1-4 mM. Gelatin-derived CQDs were prepared in a stock solution of 5 mg/ mL (w/v) from which
other solutions were prepared by dilution with K-medium (32 mM KCl, 0.3% NaCl (w/v)). The NGM
plate containing Paraquat and gelatin-derived CQDs was prepared using procedures previously
described with minor modifications203-205. During the stirring of the NGM media, the stock solution of
Paraquat and CQDs were added together to obtain a range of desired doses. 5-Fluorouracil (final
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concentration of 50 µM) was added to avoid contaminating the plates by their progeny. After the media
was adequately mixed, the solution was poured into the plate and allowed to solidify (and dry)
overnight. The plates were seeded with E. coli OP50 as the food source, which had previously been
mixed with Paraquat and gelatin-derived CQDs at the desired concentrations.
5.9. C elegans Survival Analysis
Survival assays were performed by transferring synchronized nematodes (20 animals) to freshly
prepared paraquat-containing, CQDs-containing, and control plates. The number of survivors was
recorded per hour. They were scored live or dead if they did not move when touched using a platinum
wire. The procedure was continued for 72 hours. All experiments were repeated three times.
5.10.

Protective effect of gelatin-derived CQDs on paraquat-exposed C. elegans

To evaluate the protective effect of the CQDs against paraquat-exposed C. elegans, all
aforementioned working solutions were first diluted in K-medium (32 mM KCl, 0.3% NaCl (w/v)) for
further use. Synchronized nematodes (20 µL of suspension) were pre-incubated in the CQDs at a final
concentration of 0.25 - 2 mg/mL solution and added to the 24-well plates with 250 µL solution with
OP50 for 24 hours in slow agitation. After 24 hours, worms were washed with M9 buffer and incubated
in a 2 mM paraquat solution for 72 hours.
After paraquat incubation, nematodes were washed and immobilized with 100 mM sodium
azide on the agar pad (3% agarose in DI H2O) prepared on a glass slide. All images were acquired using
a Zeiss 700 confocal microscope equipped with a 488 nm laser and using a 20X objective lens. To
examine the effect of Paraquat on dopaminergic neurons (DA), we measured the GFP fluorescence
intensities of the eight neurons. However, we only observed a loss of intensities from six neurons in the
head. Neuron loss was scored when one of the neurons revealed a loss of green fluorescence. The
fluorescence signals were quantified from each worm with ImageJ software, and the percentage of
neurodegeneration was calculated as described205, 206:
% neurodegeneration=𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑜𝑟𝑚𝑠 𝑤𝑖𝑡ℎ 𝑑𝑒𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒𝑑 𝑛𝑒𝑢𝑟𝑜𝑛𝑠 / 𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓
𝑤𝑜𝑟𝑚𝑠 𝑋 100
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5.11.

Statistical Analysis

Studies with the SH-SY5Y cell line and C. Elegans were conducted in replicates to demonstrate
the experimental viability and variability between samples. Therefore, the data represent the average
with the corresponding standard deviation (± SD). Statistical analysis was performed using a two-tailed
paired Student’s t-test if two data sets were compared. A one-way analysis of variance (ANOVA) with
Tukey Test for multiple comparisons among the group means is used to compare multiple data sets.
These tests were performed using Origin Pro 2018 (academic) software. The critical value of < 0.05
probability was defined as the level of statistical significance. Lifespan analyses were performed using
the

Online

Application

for

the

Survival

Analysis

of

Lifespan

Assays

(OASIS;

http://sbi.postech.ac.kr/oasis/introduction/). Mean lifespans were compared using the log-rank test at
more specific time points were compared using Fisher’s exact test.
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Chapter 5: Resolving the soluble-to-toxic transformation of amyloidogenic proteins: A method
to assess intervention by small-molecules

ABSTRACT
The soluble-to-toxic transformation of intrinsically disordered amyloidogenic proteins such as
amyloid beta (Aβ), α-synuclein, mutant Huntingtin Protein (mHTT) and islet amyloid polypeptide
(IAPP) among others is associated with disorders such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington’s disease (HD) and Type 2 Diabetes (T2D), respectively. Conversely, the
dissolution of mature fibrils and toxic amyloidogenic intermediates including oligomers remains
the holy grail in the treatment of neurodegenerative disorders. Yet, methods to effectively, and
quantitatively, report on the interconversion between amyloid monomers, oligomers and mature
fibrils fall short. For the first time, we describe the use of gel electrophoresis to address the
transformation between soluble monomeric amyloid proteins and mature amyloid fibrils. The
technique permits rapid, inexpensive and quantitative assessment of the fraction of amyloid
monomers that form intermediates and mature fibrils. In addition, the method facilitates the
screening of small molecules that disintegrate oligomers and fibrils into monomers or retain
amyloid proteins in their monomeric forms. Importantly, our methodological advance diminishes
major existing barriers associated with existing (alternative) techniques to evaluate fibril formation
and intervention.
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1. INTRODUCTION
A hallmark feature of neurodegenerative disorders such as AD, PD, HD and T2D is the solubleto-toxic conversion of disease-associated prion-like amyloidogenic proteins such as Aβ, α-synuclein,
mHTT, and IAPP, respectively159, 207-212. The formation of mature fibrils from their soluble, monomeric
counterparts is often the “end-point” of the amyloid-forming (amyloidogenic) trajectory. Fibril
formation is essentially irreversible. Mature fibrils, which are rich in β-sheet content, are insoluble
and therefore not easily amenable to structural studies.
Amyloid monomers are converted to mature fibrils via a sequential process that first resultsin
the formation of dimers and/or neurotoxic oligomers212 (Fig 2).
Oligomers form proto-fibrils prior to the formation mature fibrils, which is a terminal process
as aforementioned. A comparison of the kinetics of monomer consumption relative the fibril formation
is important. A difference in the rate of monomer consumption relative to fibril formation suggests the
presence of intermediates. A lag in the time to form mature fibrils is indicative of kinetically-trapped
conformations212. Quantifying the loss of monomers is essential for a detailed biophysical
understanding of the amyloidogenic trajectory. After all, it is the most experimentally tractable of all
species along the amyloid-fibril-forming pathway. The rate of monomer consumption informs us
whether the ambient conditions are biased towards retaining the monomeric conformation or towards
fibril formation. Measurement of the rate of monomer loss can be used to fine-tune ambient (fibrilforming) conditions either to intervene in the fibrillation or to promote it (say, for biophysical
studies)213. Comparison of the rate of monomer consumption with that of mature fibril formation
facilitates the generation of a kinetic and quasi- structural roadmap of the process(es) by which soluble
amyloids form insoluble aggregates.
Conversion of mature fibrils to their soluble monomeric counterparts is also indispensablefor
qualitative and quantitative evaluation of the efficacy by which small molecules may intervene
(therapeutically or prophylactically) in amyloid-forming trajectories. Molecules such as
tanshinone, brazilin and other aromatics along with specific carbon nano materials known as carbon
quantum dots and graphene quantum dots have been instrumental in passivating amyloid monomers,
remodeling oligomers, and dissolving mature fibrils157,

214-218

. With respect to small molecule

intervention, the ability to revert all non-monomeric intermediates including mature fibrils, to their
soluble monomeric counterpart is key. Also critical is the ability to localize where along the fibrilforming trajectory that a small molecule intervenes is important for further advancing the candidacy
of the said molecule212.
85

Existing techniques to identify fibrils include dynamic light-scattering (DLS), fluorescence
spectroscopy, advanced microscopy (AFM, TEM, HR-TEM, etc.), x-ray fiber diffraction, solid- state
NMR, and EPR among others32-35, 219. While each technique offers specific advantages towards the
detection of fibrils, they also require equipment that is not easily accessible, is expensive, and/or
requires extensive sample preparation. Furthermore, the quantified conversion of mature fibrils to
monomers by small molecules is not easily realized using the aforementioned techniques.
Here, we demonstrate the use of gel electrophoresis to determine whether select small
molecules revert mature fibrils to their soluble monomeric counterparts (Fig. 33).
The advantages of our method over existing techniques is discussed.

20.000 m g

Weighing Lysozyme

Gel was run for 85 minutes
At 120V and 400 A

Preparing lysozyme
monomeric solution (2mg/mL)

Incubating monomeric solution
in incubator shaker at 550 rpm
for 6 h at 58 oC

Collecting the solution after 6 h
and performing dialysis using
6 kDa dialysis bag to get rid of GdHCl

Collecting the dialyzed sample in
1.5 mL Eppendorf

collecting supernatant and pellet
in seperate
Eppendorf

Samples mixed with
4X Loading dye and ready to
be loaded into the 12%
Polyacrylamide gel

Centrifugation to collect fibrils as pellets

Figure 33: Schematic representation of steps involved in lysozyme preparation and gel
loading.
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2. RESULTS
Figure 34A is a representative TEM image of mature HEWL fibrils. The fibrils are needle-form
and well-delineated in nature. The mature fibrils appear to be interspersed with smaller, potentially,
proto-fibrillary aggregates. The data are in good agreement with previous literature220. 34B shows the
increase in fluorescence emission that results when ThT is added (@ 20s) to a solution containing
mature fibrils (black curve). The sharp and rapid increase in fluorescence intensity upon introduction
of the fluorophore is indicative of ThT binding to fibrils220. The plateauing of the curve suggests that
all fibril is either ThT bound or that there is no free ThT in solution even though there may be unbound
fibrils. By contrast, the introduction of ThT to monomeric lysozyme (red curve) did not elicit any
increase in fluorescence as anticipated.
A
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0.5

0.4
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Figure 34: A) TEM image of mature HEWL fibrils. Both fibrils and smaller potentially protofibrillar structures are evident. B) ThT assay for detecting amyloid fibrils. Red: ThT
added to asolution of lysozyme monomers. Black: ThT added to a solution containing
mature HEWL fibrils.

We determined whether gel electrophoresis could be used to qualitatively discriminate between
HEWL mature amyloid fibrils and its monomeric counterpart. Figure 35A is an image of a PAGE
experiment where HEWL monomers (35A: 1 a-d), the supernatant (35A: 2 a-d) from a centrifuged
solution containing mature HEWL fibrils and a resuspended HEWL fibril pellet (34A:3 a-d) were loaded
onto the gel. The location of the bands corresponds to the molecular weight of monomeric HEWL.
Inspection of the band intensities reveals that compared to the sample exclusively containing HEWL
monomers (35A: 1a-d), there is a decrease in the intensity of HEWL monomers in sample (35A: 2 a-d)
and a further attrition in its concentration when sampled from the fibril pellet (35A: 3 a-d). The mature
fibrils do not enter the gel due to size- exclusion.
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Figure 35B shows quantified results from the aforementioned experiment. Statistical
significance was found between samples 35B:1 and 35B:2 and samples 35B:1 and 35B:3 indicating
that PAGE can be used to quantify the soluble-to-fibril transformation of amyloid-fibril-forming
proteins.
P < 0.05
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180
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1a &b
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3a &b 1c&d

2c &d

3c &d

Integrated Density

160
140
120
100
80
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40
20
0
1

2

3
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Figure 35: PAGE of HEWL solutions. A) Protein bands corresponding to HEWL monomers is
detected across differing samples. 1a-d are monomers, 2a-d is supernatant (monomers
remaining after HEWL fibrillation) and 3a-d is the HEWL fibril pellet. B) The data are
plotted for N = 4 where p < 0.05 was observed.
After verifying the applicability of our assays in being able to resolve soluble-to-toxic
transformation of the amyloid protein, we moved forward to study what happens at different time
intervals during the fibrillation process. For this, we collected samples (supernatant and pellet) at 0,
3,4,5,6 and 9 hours (Fig 36). The samples were also tested using ThT and CD to verify this transition.
The obtained data helped us observe the evolution of cross beta architecture with time (as evident
through ThT data, Fig 36 A&B) and a decline in the alpha helical structure (as evident from CD data,
Fig 36 C&D). The samples that were run in the gel electrophoresis also followed the same trend where
a decline in monomeric/soluble part of the solution was observed with increase in time (Fig 36 E&F).
The obtained results helped us further prove that our assay could be used as a fast and facile method to
detect and quantify soluble-to-toxic transformation of the protein.
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Figure 36: Fibrillation process. A) is ThT assay of supernatant collected at different time intervals
(0-9hrs); B) is the ThT assay of pellet collected at time intervals 0-9hrs; C&D) are CD
spectra of supernatant and pellet collected at different time intervals 0-9hrs; E) is the gel
image where 1&4 are samples at T=0hrs, 2&3 are supernatant and pellets at T=3hrs;
5&6 are supernatant and pellets at T=9hrs; F) is the gel image where 1 is sample at T=0,
2&3 are supernatant and pellet at T=4 hrs, 4&5 are supernatant and pellet at T=5 hrs and
6&7 are supernatant and pellets at T=6hrs.
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We tested whether small molecules and carbon nano materials revert HEWL fibrils to their
soluble monomers. Dimethyl sulfoxide (DMSO) is known to dissociate amyloid fibrils221, 222. Figure
37A shows an increase in the concentration of HEWL monomer, relative to untreated fibrils,when mature
HEWL fibrils are exposed to DMSO. Furthermore, the difference in monomeric HEWL concentrations
between DMSO-treated fibrils and untreated fibrils is statistically significant. The data indicate that the
DMSO-driven reconversion of mature fibrils to their monomeric counterpart can easily be detected
and quantified using gel electrophoresis. (Statistically significant) difference in monomeric HEWL
concentration between the monomer control and the DMSO-treated fibrils is also notable. The fraction
of monomer released from DMSO-treated HEWL fibrils reflects the small-molecule-driven fibril-tosoluble reconversion (at the small-molecule concentration). In principle, a small-molecule doseresponse curve can be constructed to screen and rank candidate molecules.
Figure 37B shows results from HEWL fibril exposure to carbon quantum dots (CQD1: citric;
CQD2: gelatinized carbon). Although there appears to be a CQD-dependent increase in soluble
monomers relative to the untreated fibrils, the results were not statistically significant at the CQD dose
used.

Figure 37: A) HEWL fibrils treated with DMSO. Quantification of band intensity corresponding to
monomeric HEWL. Data shows the control sample (monomeric HEWL), untreated HEWL fibrils and
DMSO treated HEWL fibrils. The data are plotted for N = 2 where p < 0.05 was observed. B) HEWL
fibrils treated with CQDs. Quantification of band intensity corresponding to monomeric HEWL. Data
shows the control sample (monomeric HEWL), HEWL fibrils treated with CQDs (1: citric acid
derived and 2: gelatin-derived) and untreated HEWL fibrils. The data are plotted for N = 2 where p <
0.05 was observed.
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3. DISCUSSION
The soluble-to-toxic conversion of amyloid proteins such as Aβ, a-synuclein, mHTT among
othersis a critical milestone in the onset and pathogenesis of amyloid-specific neurodegenerative
disorders. Efforts to develop an understanding of this biophysical transformation are driven by
spectroscopic and immunohistochemical tools. Nevertheless, access to instruments such as solidstate NMR, microscopes (TEM, HR-TEM, SEM, AFM), ATR-IR, DLS instruments and
biochemical kits precludes routine studies of the process for many laboratories and investigators.
Even if high-resolution microscopes are accessible, extensive sample preparation protocols,
analyses times and availability of very specific technical/instrumentation expertise are barriers that
still need to be overcome. Finally, and critically, higher-resolution structural techniques are not
amenable to quantification and kinetics measurements. As previously noted, quantification of
oligomers and fibrils formed from soluble monomers and, perhaps more importantly, the reverse
process is important for advancing biomedical intervention. The in vitro screening of smallmolecules that intervene in amyloidogenesis precedes testing in preclinical models.
Optical methods such as DLS or fluorescence using ThT or Congo red to identify fibrils
are frequently confounded by interference from small-molecule fluorescence223. Other’s
techniques such as solid-state NMR, are not amenable to easy use, lack access, and fail to
satisfactorily quantify the interconversion between the monomeric amyloid, its intermediates, and
the mature fibril. Often, necessary sample preparation conditions do not recapitulate solution
conditions.
Through several inroads, the method described here reduce barriers towards the study of
amyloidogenesis which has traditionally involved elaborate sample preparation, mounting of
“dried” samples, expensive instrumentation, and protracted sample analyses times32. Even though
the technique is chemically and structurally “low-resolution” in nature, it provides a rapid,facile,
and inexpensive mechanism by which to quantify the loss of monomers (via their conversionto
dimers, oligomers, proto-fibrils, and fibrils), starting from a known concentration of the amyloid
nomer. Importantly, by quantifying the intensity of the bands on the gel, it permits the user to build
a kinetic profile of the consumption of monomers, formation of dimers, oligomers and finally the
transformation of the amyloid protein into mature fibrils. From a biomedical perspective, the use
of PAGE to establish a quantitative and dose-dependent profile of small-molecule efficiency in
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dissolving fibrils and oligomeric aggregates to their monomeric counterparts is highly desired.
In conclusion, we demonstrate that a readily existing method and easily accessible
apparatus can be used to obtain rich biophysical (kinetic) data about amyloid forming trajectories
and the interplay between intermediates therein. Equally importantly, it can be used to screen
small-molecules and determine, via size analysis, where along the trajectory that the smallmolecule intervenes. It provides undergraduates, graduate students and advanced biomedical
researchers in an institution with a powerful, affordable, facile method, which is already widely
available, to study an important neurodegeneration-associated process.
4. METHOD
4.1. Gel Electrophoresis 12%
Gels were prepared as described elsewhere224. Briefly, for the running buffer, 1650 uL of
water, 2000 uL of 30% acrylamide, 1250 uL of 1.5 M Tris (pH 8.8), 50 uL 10% ammonium
persulfate and 2ul TEMED was combined in a 15 mL falcon tube and transferred to the slides.
Later, the layering was completed using tertiary butanol. The gels were allowed to polymerize for
about 20 minutes. The stacking solution containing 1550 uL of water, 250 uL of 30% acrylamide,
190 uL of 1.5 M Tris (pH 6.8), 15 uL ammonium persulfate and 1.5 ul TEMED in a 15 mL falcon
tube was introduced into the gel on top of the running gel. The stacking gel was left to polymerize
for 15 minutes and then stored at -4 oC until further use (using wet Kim-wipes covered with the
aluminum foil).
4.2. Preparation of Lysozyme solutions
2 mg/mL of Hen-Egg White Lysozyme (HEWL; Sigma) solution in freshly made
potassium phosphate buffer (20 mM, pH =6.3, 3M Guanidinium Hydrochloride) was prepared in
a 5 mL glass vial and kept in an incubator-shaker at 550 rpm at 58 oC for t=0,3,4,5,6,9hrs. After
t=6hrs, (the contents of the glass vial were turbid), mature fibrils were visualized using
Transmission Electron Microscopy184.
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4.3. Loading of amyloid samples onto the gel
The aforementioned solution was dialyzed and added into 1.5 mL Eppendorf tubes and
centrifuged (12,400 rpm for 15 minutes). The supernatant was collected in 1.5 mL Eppendorf tubes
and DI water was added to the pellet and mixed well. 30 uL of the solution (including supernatant
and pellet) was then transferred in separate 0.5 mL pre-labelled Eppendorf tubes. Later, 10 uL of
4X loading dye was added to 30 uL of supernatant and pellet solution. Monomeric solution of
Lysozyme (2mg/mL) was prepared as a control and 30 uL was mixed with 10 uL of 4X loading
dye. The samples were heated at 95 oC for 5 minutes and 20 uL of this solution was then loaded
into the wells of the gel. The gel was then run for 85 minutes at 120V and 400 A. For stainingdestaining, gels were removed from the glass slides and rinsed with water. Later, the gels were
submerged in Coomasie staining solution overnight. The next day, destaining was performed
using 1:1 :0.2 ratio of water: methanol: acetic acid. Destaining was repeated thrice for 20 minutes
each. After the third destaining wash, the gel was submerged in water to, and an image was
subsequently obtained using the Invitrogen iBright Imaging system.
4.4. Imaging of HEWL fibrils
For Transmission electron microscopy analysis, samples were suspended in deionized
water and sonicated for 5-10 minutes before adsorption to carbon-coated Cu grids (Electron
Microscopy Sciences, Hatboro, PA) followed by negative staining with 2.5% uranyl acetate.
Excess stain was adsorbed with Whatman #1 filter paper and grids were air dried and viewed in
amodel H-7650 transmission electron microscope operated at 80 kV (Hitachi High-Technologies,
Dallas, TX). Digital images were collected with an AMT XR 60 CCD camera system (Advanced
Microscopy Techniques, Woburn, MA).
4.5. Fluorescence assays
Lysozyme samples were aliquoted for analysis after 0,3,4,5,6,9 hours of incubation.
Thioflavin T fluorescence (20 μM) was used to determine the fibril content of each sample in a
DM45 Olis Spectrofluorometer using 450 nm and 480 nm as excitation and emission wavelengths,
respectively.
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4.6. Circular Dichroism studies
The solutions from the vials (40 µL) were added to the cuvette (fireflysci.com) and
measurements was obtained using the Circular Dichroism (JASCO 1500). The parameters were
fixed at bandwidth = 1.00 nm, measurement range = 190-260 nm, data pitch = 0.1 nm, scanning
speed = 50 nm/min, and accumulation = 3 times.
4.7. Data Analysis
The obtained images of the gel using the iBright imaging system were analyzed using
theImage J software. The data obtained from Image J were transferred to Origin Pro software
and mean and standard deviation values are calculated for each band. The bar graph is plotted
againstIntegrated Density vs Samples.
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Chapter 6: Conclusion

There are three contributions of this dissertation. The first one involves development of
nanocarriers for controlled and sustained release of an encapsulated drug. In this work, we aimed
at enhancing the solubility, permeability, and bioavailability of Ellagic drug, a class IV
biopharmaceutics classification system (BCS) drug. The drug is a potent antioxidant but suffers
from dose-dependent toxicity at higher doses. To overcome these limitations, we encapsulated the
drug inside a container which was not passive but instead itself had neuroprotective properties.
Chitosan was used as nanocarrier because of its excellent biocompatibility, low toxicity, and
biodegradability. It is classified as “Generally regarded as safe” (GRAS) for use by FDA. The
nanoparticles were synthesized using ionic-gelation method which is a mild synthesis method (no
high temperature and heat required, and minimal organic solvents used). A controlled and sustained
release of drug from the nanocarrier was observed after initial burst release. The burst release could
be attributed to the drug anchored on the surface of the nanocarrier or drug trapped near the surface
of the nanocarrier. The initial burst release allowed availability of drug in case of acute oxidative
attack whereas sustained release would enhance the lifetime and bioavailability of the drug. In case
of drug loaded nanoparticles (EA@PCS), enhanced neuroprotective activity was observed
compared to drug and bare nanoparticles when cells were insulted with rotenone, the cell stressor.
The FTIR and UV-VIS data also pointed towards the potential interactions between the drug loaded
nanoparticles and rotenone which could be preventing it from binding to complex I of ETC and
inducing oxidative stress. Hence, it could be concluded that this sustainably-derived drug loaded
nanoencasement could be used as a prophylactic drug for treating PD patients.
The second objective of this work was to develop a multifunctional drug that could be used
to overcome more than one molecular output associated with the disease. Studies have shown that
proteopathy and mitochondrial dysfunction initiates redox imbalance and vice-versa. Therefore,
there is a urgent need for the development of a "one-pot" drug which also intervenes across
multiple disease outputs. This facet is becoming increasingly important as diseases are being
recognized as not being monogenic in nature but instead as progressing via a plethora of molecular
aberrations that are sporadic/idiopathic. To achieve this objective, we developed cqds from organic
acids (sodium citrate, phenylboronic acid, and 4-aminophenylboronic acid) and protein (gelatin)
via one-step hydrothermal method. The as-synthesized sustainably derived cqds displayed
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neuroprotective properties in vitro (all four) and in vivo (gelatin-derived cqds) against pesticidesinduced oxidative stress and associated neuronal demise. Hence, it could be concluded that cqds
have neuroprotective capabilities.
The last part of the dissertation focuses on the development of cost-effective, inexpensive,
and facile method to resolve soluble-to-toxic transformation of amyloid proteins. Existing
techniques such as solid-state NMR, microscopes (TEM, HR-TEM, SEM, AFM), ATR-IR, and
DLS are expensive, require extensive sample preparation protocols, analysis time and availability
of very specific technical/instrumentation expertise. Whereas, gel electrophoresis apparatus is
readily available in all biology, biochemistry and nanobiotechnology labs. It is simple to use,
require minimal sample to perform the experiment, cost-effective, and experiment is less tedious
and time consuming. The proposed technique could be used not only to validate the presence or
absence of the monomers in the solution, but it could be used to track the consumption of monomer
at different time interval along the amyloid forming trajectory. This could help us in building
kinetic profile of the process as the monomer’s transitions to fibril. The method would also provide
quantitative data which is not possible with other above-mentioned techniques. Our results also
show the possibility of using this technique to quantify the disintegration of fibrils using small
molecules. In conclusion, we demonstrate that a readily existing method and easily accessible
apparatus could be used to obtain rich biophysical (kinetic) data about amyloid forming trajectories
and the interplay between intermediates therein.
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